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ABSTRACT 
       Heart diseases are the leading cause of death worldwide. Despite the development of a 
broad array of treatment options, current therapies only delay progression of the disease 
and failed to prevent myocardial scar formation and replace the lost cardiomyocytes 
(cardiac muscle cells). Over the past decade the use of adult stem cells,  particularly bone 
marrow derived mesenchymal stem cells, to safely facilitate recovery of cardiac function 
after myocardial infarction has received a lot of interest. Mesenchymal stem cells (MSCs), 
which are adherent stromal cells of a non-hematopoietic origin, have great differentiation 
potential and under appropriate in vitro culture conditions can trans-differentiate into 
cardiomyocyte cells. This study investigated the characterization of rat bone marrow 
derived-mesenchymal stem cells (BM-MSCs) and in vitro differentiation potential of them 
into cardiomyocyte- like cells by two DNA-demethylating agents, 5-azacytidine and 
zebularine. MSCs were isolated from Sprague Dawley’s bone marrow and cultured in 
complete Dulbecco’s Modified Eagle Medium (DMEM).  Morphological characteristics of 
MSCs were analyzed by phase contrast microscopy. Selected surface antigens CD44, 
CD117, known MSCs markers, and CD34, a hematopoietic marker (negative marker), 
were analyzed by immunocytochemistry. In addition, CD45, known hematopoietic marker 
(negative marker) and CD44 were analyzed by flow cytometry for the MSC cell population 
count. Passage 1 (P1) cultured MSCs were then treated in separate culture flasks for 24 
hours with a 3µM optimized concentration of 5-azacytidine and zebularine. After 20 days, 
treated cells were analyzed for the expression of rat cardiac specific genes; namely, alpha-
myosin heavy chain (CAMHC), cardiac troponin-T (cTnT), and cardiac transcription factor 
(GATA-4) by reverse transcriptase polymerase chain reaction (RT-PCR). The endogenous 
housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an 
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internal standard gene for normalization of mRNA. The isolation of MSCs from rat bone 
marrow was successfully completed. Isolated MSCs exhibited spindle-shaped morphology 
with adherence ability to the surface of flasks and proliferated in the culture medium. 
Immunocytochemistry results showed that cell surface antigen expression was observed to 
be positive for CD44 and CD117. However, MSCs were negative for CD34 (hematopoietic 
marker); hence, confirming the absence of hematopoietic cells. Furthermore, CD44 was 
found to be >85% positive, while CD45 was more than 60% negative in MSCs after flow 
cytometry cell population analysis. Upon induction with 5-azacytidine and zebularine, the 
morphology of the MSCs changed and the cells showed extended cytoplasmic processes 
with ball- like appearance. After 20 days, they were connected with adjoining cells forming 
myotube- like structures. The mRNAs of CAMHC, cTnT and GATA-4 were detected in 
both treated and untreated cells. However, RT-PCR analysis for the expression of cardiac 
specific genes showed that treated MSC cells expressed cTnT, CAMHC and GATA-4 
significantly higher compared to untreated cells. While there were no significant 
differences between 5-azacytdine and zebularine treated cells, zebularine could be a good 
replacement for 5-azacytidine as it is more stable and less toxic to biological system. These 
results showed that bone marrow mesenchymal stem cells (BM-MSCs) could differentiate 
in vitro towards a cardiomyogenic lineage. 
 
 
 
 
 
iv 
 
ABSTRAK 
         Penyakit jantung adalah punca utama kematian di seluruh dunia. Walaupun terdapat 
kemajuan dalam pelbagai opsyen rawatan, terapi semasa hanya dapat melambatkan 
perkembanga  penyakit dan gagal untuk menghalang pembentukan  parut miokardium dan 
menggantikan kardiomiosit sel-sel yang hilang. Sepanjang dekad yang lalu, penggunaan 
sel  stem dewasa, terutamanya sel-sel stem mesenkimal yang diperolehi dari sum-sum 
tulang untuk memudahkan pemulihan fungsi jantung dengan selamat selepas infarksi 
miokardium telah mendepat banyak pnumpuan. Sel-sel stem mesenkimal (Mesenchymal 
Stem Cells) yang merupakan sel stromal adherent yang bukan berasal dari hematopoietik, 
mempunyai potensi yang besar dalam pembezaan/diferensiasi dan di bawah keadaan in 
vitro kultur yang sesuai boleh trans-diferensiasi untuk menjadi sel kardiomiosit. Kajian ini 
menyiasat tentang pencirian sel-sel mesenkimal yang diperolehi dari sum-sum tulang tikus 
(BM-MSCs - Bone Marrow Mesenchymal Stem Cells) dan potensi diferensiasi in vitro sel-
sel tersebut menjadi sel-sel mirip kardiomiosit dengan menggunakan  dua ejen demetilasi 
DNA, 5-azacytidine dan zebularine. MSCs telah diasingkan daripada sum-sum tulang 
Sprague Dawley dan dikultur di dalam Dulbecco's Modified Eagle Medium (DMEM) yang 
lengkap. Ciri-ciri morfologi MSCs dianalisa dengan menggunakan mikroskop fasa-
kontras. Antigen permukaan yang terpilih CD44, CD117, yang dikenali sebagai penanda 
bagi MSCs, dan CD34, suatu penanda bagi hematopoietik (penanda negatif), dianalisa 
dengan immunositokimia. Sebagai tambahan , CD45, iaitu penanda bagi  hematopoietik 
(penanda negatif) dan CD44, dianalis dengan flow cytometry untuk mendapatkan bilangan 
populasi sel-sel  MSC. Pasaj 1 (P1) MSC yang telah dikulturkan kemudiannya dirawat di 
dalam kelalang kultur yang berasingan selama 24 jam dengan kepekatan 3μM  5-
azacytidine dan zebularine  yang telah dioptimakan. Selepas 20 hari, sel-sel yang telah 
v 
 
dirawat dianalisa untuk ekspresi gen-gen spesifik jantung tikus; iaitu alpha-myosin heavy 
chain (CAMHC), cardiac troponin-T (cTnT), dan cadiac transcription factor (GATA-4) 
dengan menggunakan reverse transcription polymerase chain reaction (RT-PCR). BM-
MSC yang telah diasingkan mempamerkan morfologi berbentuk gelendong dengan 
keupayaan melekat kepada permukaan kelalang dan telah berkembang biak dalam medium 
kultur. Keputusan immunositokimia menunjukkan bahawa ekspresi antigen permukaan sel 
diamati positif untuk CD44 dan CD117. Walau bagaimanapun, MSC adalah negatif untuk 
CD34 (penanda bagi hematopoietik), oleh itu, mengesahkan ketiadaan sel-sel 
hematopoietik. Tambahan pula, CD44 didapati > 85% positif, manakala CD45 (penanda 
hematopoietik); adalah lebih daripada 60% negatif dalam MSC melalui analisis populasi 
sel menggunakan flow cytometry. Setelah induksi menggunakan 5-azacytidine dan 
Zebularine, morfologi MSC telah berubah dan sel-sel mempamerkan unjuran proses 
sitoplasm dengan penampilan seperti bebola. Selepas 20 hari, sel-sel yang bersebelahan 
telah berhubung dan membentuk struktur seperti miotiub. mRNA bagi CAMHC, cTnT and 
GATA-4, dan GATA-4 telan dikesan dalam kedua-dua sel dirawat dan tidak dirawat. 
Walau bagaimanapun, analisis RT- PCR untuk ekspresi spesifik gen kardiak menunjukkan 
bahawa sel-sel MSC yang dirawat mempamerkan kehadiran cTnT, CAMHC dan GATA-4 
yang signifikannya lebih tinggi berbanding sel-sel yang tidak dirawat. Manakala, tidak ada 
perbezaan yang signifikan di antara sel-sel yang dirawat 5-azacytidine dan zebularine. 
Zebularine boleh menjadi pengganti yang baik untuk 5-azacytidine kerana ia lebih stabil 
dan kurang toksik kepada sistem biologi. Keputusan ini menunjukkan bahawa sel sum-sum 
tulang mesenkima (BM- MSC) boleh didiferensiasi secara in vitro menjadi  kumpulan 
kardiomiogenik. 
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CHAPTER 1 
INTRODUCTION 
 Heart disease is one of the most leading causes of mortality globally (Mendis et al., 
2011). It is estimated that around 23.6 million people will die from cardiovascular diseases 
by 2030 (Elnakish et al., 2012). Diseases such as diabetes, coronary artery diseases, and 
myocardial infarction are best known by the irreversible loss of specific cell types that lead 
to dysfunction of heart’s tissue, which will cause limitation of heart for self-renewal and 
regeneration (Woodbury et al., 2000; Melo et al., 2004; Lu et al., 2006).  
  Due to high mortality and morbidity rate associated with coronary heart diseases 
novel methods to improve their function are highly demanded (Kumar et al., 2012; Naeem 
et al., 2013). More than a century of researches into the etiology, pathophysiology and 
pathology of acute myocardial infarction have given rise to many mechanical and 
pharmacological approaches to improve the quality of life for sufferers and extend their 
healthy lifespan. However, these treatment methods are limited to delaying or reducing the 
functional decline experienced by patients and cannot restore lost function (Davy, 2011 ; 
Elnakish et al., 2012).  
 Within the last decade, scientists have tried to find ways to cure and regenerate lost 
myocardium and restore cardiac function. In order to overcome these obstacles scientists 
have introduced cell-based therapeutic approaches to treat the damaged heart (Psaltis et al., 
2008). The discovery of differentiated potential of stem cells has opened new windows in 
the field of regenerative medicine. Regenerative medicine or stem cell therapeutics is a 
rapidly emerging field and gaining substantial attention for research and clinical 
applications. Regenerative medicine involves the repair or regeneration of an organ tissue 
or cells in order to restore an impaired function of the tissue (Psaltis et al., 2008). The 
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goals of stem cell based cellular therapy are the same as all regenerative medicine 
strategies; which is to recover function in a damaged or diseased organ or system that lacks 
sufficient regenerative capacity to heal unaided. The main goal is to repair and cure injured 
and diseased organ and tissue with living, home-grown replacement, not with mechanical 
devices like insulin pumps and titanium joints. It would be the beginning of a new era of 
regenerative medicine, one of the holy grails of modern biology.  
 The use of stem cells in medicinal therapy is a promising therapeutic approach for a 
variety of diseases including heart diseases (Mendis et al., 2011; Elnakish et al., 2012). For 
instance, acute and chronic heart disease related functional losses are most probably the 
biggest targets of cellular therapy research and clinical trials to date. Although some 
previous works had suggested that adult stem cells offered myocardial regenerative 
potential, research into the efficacy and mechanisms involved exploded only in the last 
decade.   
 Multipotent adult stem cells, such as bone marrow mesenchymal stem cells (BM-
MSCs) have become one of the interesting and important candidates in cardiac cellular 
therapy. The unique properties of MSCs are that  they could be easily isolated and 
proliferated from the bone marrow (Caplan & Dennis, 2006), immunologically tolerated as 
an allogeneic transplant (no immune rejection) (Uccelli et al., 2008) and their multilineage 
potential (Pittenger et al., 1999). These characteristics of MSCs have lead to intense 
investigation as a cell-based therapeutic for cardiac repair.  
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1.1 General Objective: 
       The main aim of this study is to isolate, proliferate and characterize bone marrow 
mesenchymal stem cells (BM-MSCs) and explore cardiomyogenic differentiation potential 
of these cells through induction by optimized concentration of two compounds, namely 5-
azacytidine and zebularine.  
 
1.1.1 Specific Objectives: 
The general objective will be achieved through specific objectives as follows: 
1. Isolation and proliferation of bone marrow derived mesenchymal stem cells (BM-
MSCs) from rat bone marrow. 
2.  Characterization of  (BM-MSCs) by: 
(a)  Immunocytochemistry  
(b) Flow Cytometry  
3. Trans-differentiation of BM-MSCs into cardiac- like cells by treating with: 
(a)  5-azacytidine  
(b)  Zebularine  
 
4. Analyze gene expression level of selected cardiac specific genes of treated and 
untreated MSC cells by reverse transcriptase (RT) PCR.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Historical Overview: 
  Highlighted by several historical breakthroughs, stem cell biology saw its rebirth at 
the end of the last century. In 1997, the world was surprised by Wilmut and his group, who 
demonstrated that the nucleus of a somatic cell showed full genetic potential b y giving 
birth to Dolly sheep after injecting it into a denucleated oocyte. A year later, Thomson et  
al. (1998) developed an isolation and culture method to maintain human embryonic stem 
cells in vitro.  
 In the field of adult stem cell research, Friedenstein and his colleagues (1970) were 
the first investigators to demonstrate that bone marrow consist of a mixed population of 
hematopoietic stem cells (HSCs) and a rare population of plastic-adherent stromal cells, 
which is now commonly called mesenchymal stem cells (MSCs). Friedenstein identified 
the importance of MSCs in controlling and supporting the hematopoietic niche and he also 
demonstrated the differentiation ability of MSCs into mesodermal derived tissue. Piersma 
et al. (1985) and Caplan (1986) showed differentiation of MSCs into osteoblasts, 
chondrocytes, and adipocytes. During the 1990s, differentiation of MSCs into a myogenic 
phenotype was shown (Wakitani et al., 1995). Ferrari et al. (1998) first reported the trans-
differentiation of bone marrow stem cells into muscle tissue and the same year  Shi et al. 
(1998)  followed by reporting the endothelial tissue from bone marrow. 
 In early 21st century, differentiation of MSCs into endodermal derived cells and 
cardimyocytes in vivo were studied (Toma, 2002; Sato et al., 2005). Within this time, Di 
and colleagues (2002) stated MSCs can suppress T- lymphocyte proliferations. This study 
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attracted scientists’ attention for application and potential of MSCs therapy for allogenic 
transplantation and immunomodulatory. MSC therapy has been recently moved to pre-
clinical and clinical trials for cardiovascular  disease (CVD) (Hare et al., 2009).  These 
reports of the adult stem cell multipotency changed the view of the old paradigm in cell 
biology and opened new possibilities for treating human diseases. With the findings of 
adult stem cell plasticity, it becomes possible to replace the injured or senile tissues by 
either stimulating the proliferation of endogenous adult stem cells, or grafting allogenic 
progenitors derived from an exogenous source (Williams et al., 2011).  
2.2 What are Stem Cells 
  Stem cells are defined as undifferentiated cells that have the ability to self-renew 
(self-replicate) and differentiate themselves into other types of cell such as blood, muscle, 
skin and brain cells. They can self-replicate for indefinite periods in the human body 
through process of “proliferation”. When cells replicate themselves many time over it is 
called “proliferation”  (Swanepoel, 2006). During human development, after fertilization, 
the fertilized egg (zygote) ultimately give rise to more than 200 cells types such as blood 
cells, liver cells, skin cells and neural cells that make up the human body. This process, 
which less specialized cells turn into more specialized cell types, is called “differentiation” 
(Enmon, 2002; Kumar et al., 2012). Stem cells can replicate and differentiate many times, 
unlike muscle cells, blood cells and nerve cells which do not normally replicate 
themselves. One of the characteristic of a stem cell is that it does not have a tissue-specific 
structure that allows it to perform specialized functions (Ma, 2010). For instance, unlike 
heart muscle cells which works together systematically with a complete heart structure to 
pump blood or red blood cells which carry molecules of oxygen through blood stream, a 
stem cell could not do this sort of work on its own. However unspecialized stem cells, by 
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coordinating their gene expression in an elaborate and complex pattern span many 
generation of cells,  have the ability to differentiate to complex cells or tissue, such as heart 
muscle cells, blood cells, nerve cells and many other types of cells (Swanepoel, 2006; Ma, 
2010).   
  
2.3 Importance of Stem Cells  
  Self-renewal, proliferation and differentiation potential of stem cells into other cell 
types have made them as a leading candidate in order to repair and replace  damaged tissue 
and organs. Scientists hope to overcome and treat many common diseases, including heart, 
kidney, liver and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases 
by using these cells. A better understanding and control of stem cell proliferation and 
differentiation in vitro would benefit many other areas such as drug testing, cancer research 
and fundamental research on embryonic development. Researchers also hope that stem cell 
research will help lead to the application of other therapeutic treatment called gene therapy. 
By understanding the human genome, scientists can identify genetic inconsistencies that 
lead to disease and modify them by introducing a corrective genetic remedy. Stem cell 
treatment, unlike most conventional drug treatment, has the potential to become a lifelong 
cure. There is almost no realm of medicine that would not be touched by this innovation. It 
is not too unrealistic to say that this research has the potential to revolutionize the practice 
of medicine and improve the quality and length of life. However, to exploit and apply the 
therapeutic potential and promises of stem cells, extensive researches need to be done on 
the risks and benefits of their use and applications (Swanepoel, 2006). 
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2.4 Types of Stem Cells  
        There are different sources of stem cell which differ in their potential for 
differentiation and in the number of cell types to which they can normally give rise. They 
are usually categorized in term of  how committed they are to becoming any particular type 
of cells, namely “Totipotent stem cells”, “Pluripotent stem cells” and “Multipotent stem 
cells”(Thomson et al., 1998; Laurie, 2004;Takahashi et al., 2007)(Figure 2.1). 
 
2.4.1 Totipotent Stem Cells  
 As mentioned earlier, Stem cells are defined as having two essential properties: the 
ability to self- renew and reconstitute their own population, and the ability to differentiate 
into multiple different types of mature daughter cells. The latter ability is referred to as the 
cell’s potency, and several different levels of potency exist during the development of an 
organism. Human cells can be divided into sex or germ cells; (eggs and sperm cells); and 
somatic cells (the rest of body cells). When a sperm cell and an egg cell unite, they form a 
fertilized egg or zygote. After fertilization, zygote starts dividing to initially form two, then 
four, then eight identical cells. These cells are totipotent, which means they have the ability 
to give rise to any and all human cells, such as heart cells, brain cells and liver cells as well 
as the extra-embryonic tissues such as the placenta or yolk sac (Thomson et al., 1998). 
Totipotent cells exist for a short time between fertilization and the formation of the 
blastocyst.  
 
2.4.2 Pluripotent Stem Cells 
 During embryonic development, on the fourth day, the ball of cells forms into an 
outer layer known as a “blastocyst”. The blastocyst is a small, hollow ball that consists of 
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around hundreds relatively undifferentiated cells. Each blastocyst consists of two layer, the 
outer cell mass, which develops into extra embryonic tissue such as placenta and other 
tissue needed for fetal development in the uterus, and the inner cell mass, which is a group 
of about 30 cells that will produce tissues for the resulting child (Swanepoel, 2006). These 
cells are pluripotent cell, which have the potential to develop into any of the 200 cell types 
that make up the human body (Laurie, 2004). Thus, pluripotent cells in the inner cell mass 
of the blastocyst are a source of human embryonic stem cell lines (Thomson, 1998; Laurie, 
2004). Pluripotent cells could eventually differentiate into any bodily tissue, but they 
cannot develop into a human being themselves, because they are unable to give rise to the 
placenta and other tissues required for full human development. Therefore, they would not 
be able to develop into a fetus if placed in a woman’s uterus. These cells have lost the 
ability to form the extra-embryonic tissues, but still have the ability to form all three germ 
layers of the developing embryo (endoderm, mesoderm, and ectoderm). The pluripotent 
stem cells further specialize into other type of stem cells. These cells, which can only 
develop into a few tissues, are called multipotent stem cells (Enmon, 2002).  
 
2.4.3 Multipotent Stem Cells: 
 Multipotent stem cells exist in many organs and tissues, including bone marrow, 
fat, peripheral blood, skeletal muscle, skin, heart, liver and even the brain. Adult stem cells 
are characterized as multipotent stem cells. These multipotent stem cells can differentiate 
in vitro and currently being studied for their purpose use in regenerative med icine (Enmon, 
2002; Ma, 2010). Multipotent adult stem cells are attractive stem cell resources for the 
replacement of damaged tissue or organ in regenerative medicine. They can give rise to 
cells that have a particular function. For example, hematopoietic stem cells give rise to red 
9 
 
blood cells, white blood cells and platelets, while skin stem cells give rise to the different 
types of skin cells. These organ specific stem cells form during fetal development and 
remain in adult individuals. They are undifferentiated cells with the capability of self-
renewal and a high rate proliferation which have potential to differentiate into specialized 
cells with specific functions (Pittenger et al., 1999). Despite of limitation and restriction of 
using multipotent adult stem cells for differentiation into a particular lineage such as 
mesodermal, endodermal or ectoderm, they have the potential and ability to differentiate 
into distinct somatic cell types with appropriate stimulation. Unlike pluripotent embryonic 
stem (ES) cells, adult stem cells can avoid some ethical issues associated with ES cells, 
resulting in a more timely approval for research and therapeutic use. Another advantage of 
using adult stem cells is that the derivation and transplantation of these cells believed to be 
less likely to initiate rejection when they transplanted. Although adult stem cells believed 
to be a promising candidate for the treatment of many diseases in the field of regenerative 
medicine and cellular therapy, many aspects remain to be explored in order to guarantee 
appropriate quality assurance and control of these cells, such as avoiding inappropriate 
gene expression in transplanted cells or the undesirable traits of tumorigenesis (Reik, 
2007). 
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Figure 2.1: Different types of stem cells: Totipotent zygote gives rise to the blastocyst. 
Pluripotent embryonic stem cells derived from the inner cell mass of the bla stocyst. 
Multipotent adult stem cells exist in many mature tissues, used as a reservoir of renewing 
cells (Retrieved from Netanely, 2006).  
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2.5 Sources of Stem Cells 
 Until 2006 based on development stage, scientists dealt with two kinds of stem 
cells namely, embryonic stem cells (ESCs) and adult stem cells (ASCs). However, in 2006, 
scientists made breakthrough by introducing new kind of stem cell by identifying 
conditions that allow some specialized adult cells to be reprogrammed genetically to 
assume a stem cell- like state. This new type of stem cell, called “Induced Pluripotent Stem 
Cells” (IPSCs). Therefore, there are now three kinds of stem cells: embryonic stem cells  
(Adewumi et al., 2007), adult/somatic stem cells (ASCs) (Young & Black, 2004) and 
induced pluripotent stem cells (iPSCs), which is recently discovered by Japanese scientist 
(Takahashi et al., 2007). Although these cells carry overlapping properties, they are 
different in their general properties and potential which will be discussed in later sections.  
 
2.5.1 Embryonic Stem Cells (ESCs): 
 Embryonic stem cells (ESCs) are derived from early embryos that can be 
propagated indefinitely in the primitive undifferentiated state while remaining pluripotent. 
Specifically, ESCs are derived and isolated from embryos that developed from fertilization 
of eggs in vitro at in vitro fertilization (IVF) clinics. They are never derived from eggs 
fertilized in a woman’s body. They are isolated from the inner cell mass of blastocyst, 
which comprises 16 to 140 cells. These stem cells could also be obtained from aborted 
fetuses and could also be derived through somatic cell nuclear transfer techniques for 
therapeutic purposes (Adewumi et al., 2007).  
 Murine embryonic stem cells were first isolated in 1981 (Evans & Kaufman, 1981) 
and human embryonic stem cells were isolated in 1998 (Thomson, 1998). Embryonic stem 
cells exhibit normal and stable karyotype, express embryonic cell surface markers and can 
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be cultured in vitro for very long periods in an undifferentiated state and yet retain their 
pluripotent differentiation potential. Upon induction by specific differentiation compounds, 
cultured ESCs can differentiate in-vitro into a variety of mature cell types, including: 
neurons, skin cells, blood, muscle, cartilage, endothelial cells, cardiac cells and pancreatic 
cells (Adewumi et al., 2007).  ESCs have gained a lot of attention because they are 
immortal and have almost unlimited development potential. However, human embryonic 
stem cell research which holds the greatest potential for regenerative medicine has proven 
to involve the greatest difficulties as well. Unfortunately, the generation of human ESCs 
lines has sparked a great deal of controversy, particularly in certain religious communities 
(Orive et al., 2003).  
 2.5.2 Induced Pluripotent Stem Cells (iPSCs) 
  Induced pluripotent stem cells (iPSCs) are induced from reprogrammed fibroblasts 
by the retrovirus mediated introduction of Oct3/4, Sox2, c-Myc and Klf4, transcription 
factors that unlock all restrictive conditions of a differentiated cell and reverse the 
biological clock to provide pluripotency (Takahashi et al., 2007; Gonzalez et al., 2011;  
Robinton & Daley, 2012). Scientists are using iPSC technology for generation of new 
types of cells by reprogramming adult stem cells with the same potential as ESCs rather 
than using ESCs which involve many ethical issues. Within last few years, scientists have 
created iPSCs from multiple human tissues, including lung fibroblasts, keratinocytes 
(Aasen et al., 2008), fibroblast- like synoviocytes (Takahashi et al., 2007), cord blood 
(Giorgetti et al., 2009; Haase et al.,2009), peripheral blood (Loh et al., 2009), 
mesenchymal stromal cells (Oda et al., 2010), oral mucosa fibroblasts (Miyoshi et al., 
2010) and T-cells (Loh et al., 2010; Seki et al., 2010) (reviewed by Aránega, 2011). The 
ability to reprogramme somatic cells into iPSC cells that are pluripotent, self-renewal and 
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self-replication potential has transformed the field of regenerative medicine (Aranega, 
2011). However their complete potential and possible toxicity is yet to be assessed before 
any future use in clinical setting (Takahashi et al., 2007; Okita et al., 2007). 
2.5.3 Adult Stem Cells (ASCs) 
 Following fetal and childhood development, the organs and tissues of adult humans 
and animals generally maintain their size and structure. This stable external appearance of 
tissue hides the fact that tissue maintenance is a steady state process; dying cells must be 
replaced continuously throughout life. Organs and tissues have distinct rates of turnover, 
which is related to their function (Rizvi et al., 2005). The term adult stem cell (ASCs) or 
somatic stem cell refers to the cells found in adult organisms that constantly replenish the 
somatic cells in the tissue of their origin. Scientists defined them as cells of the body (not 
the germ cells, sperm or eggs). 
  ASCs are multipotent stem cells, which are capable of self-renewal throughout the 
organism’s life, and also capable of differentiating into various mature cell types usually 
through an intermediate cell of increased commitment (progenitor). Therefore, adult stem 
cells are already committed to a certain cell lineage and, thus, they are restricted in their 
differentiation range and this characteristic makes them to be referred to as multipotent 
stem cells. Multipotent adult stem cells reside within mature tissues and serve as a limitless 
source for new mature cells, enabling maintenance and repair of the tissue by continuously 
regenerating mature tissues, either as part of normal physiology or as part of repair after 
injury. Although the existence of these ASCs is beyond doubt in most cases, their isolation 
and identification proved to be difficult. It is important to assess the in vitro differentiation 
capability of these cells, which may reflect their developmental potentia l. In recent studies, 
the concept of multipotency of ASCs has moved to the forefront of stem cell research. 
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Studies have shown that  multipotent ASCs have the ability to retain much of the 
multipotentiality of their embryonic and fetally-derived counterparts, compared to ESCs 
with the many ethical issues surrounding its use (Swanepoel, 2006; Li & Clevers, 2010; 
Humphreys, 2011). Scientist have discovered and derived adult stem cells from many 
sources including the bone marrow, umbilical cord, adipose tissue, kidney, blood, liver and 
certain regions of the adult brain. To date, bone marrow stem cells is the most accessible 
and least invasive source of multipotent adult stem cell (Irons, 2007; Ma, 2010) which is 
the focus of this thesis. 
2.6 Bone Marrow Niche 
 The bone marrow (BM) is a spongious and fatty tissue that contains a multitude of 
cell types and niches. BM is a complex tissue consists mainly of two different tissue types, 
hematopoietic (HSCs) and stromal/mesenchymal stem cells (MSCs) with function of 
supporting hematopoiesis. Each of these tissues is home to important forms of adult stem 
cells (ASCs) namely, hematopoietic stem cells (HSC), mesenchymal stem cells (MSC) and 
endothelial progenitor cells (EPCs), respectively.   
 HSCs are the major source of cells within bone marrow. The HSCs are developed 
and supported in the bone marrow microenvironment, termed the hematopoietic niche, and 
the MSCs are one of the most important cell type that support BM microenvironment 
(Prockop, 1997; Pittenger & Martin, 2004). MSCs are known as marrow stromal cells 
because they were originally identified as forming a tiny proportion of the no n-
hematopoietic stromal tissue. The rest of the stroma consists of fibroblasts, macrophages, 
adipocytes, osteoblasts and endothelial cells. They contribute to connective tissue, defense, 
nutrient delivery, bone tissue management, and vascular structure, respectively. All of 
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which contribute in some way to the formation and maintenance of the stem cell niches 
(Herzog et al., 2003; Davy, 2011).  
2.6.1 Endothelial Progenitor Cells (EPCs) 
 Endothelial progenitor cells are a circulating bone marrow cells that contribute to 
the endothelium and participate in both vasculogenesis and vascular homeostasis (Khakoo 
& Finkel, 2005). Existence of a bone marrow–derived circulating progenitor for the 
endothelial lineage called the endothelial progenitor cell (EPC) was first reported in 1997 
(Asahara, 1997). They were originally isolated from peripheral blood as CD34+ circulating 
progenitor cells and were later determined to originate in the bone marrow (Asahara, 
1997). Several studies have elucidated and reported the roles of putative bone marrow–
derived EPCs in cancer ( Young & Black, 2004; Kim et al., 2005; Kaplan et al., 2006; ), 
cardiovascular disorders (Werner et al., 2005; McNeer, 2007), and diabetes (Eizawa et al., 
2004; Loomans et al., 2004; Fadini et al.,  2007). 
2.6.2 Hematopoietic Stem Cells (HSCs) 
 Hematopoietic stem cell (HSC) is one of the first well-known and most-studied 
ASCs in bone marrow. It is also the most successful example of “stem ce ll therapy” 
(Kuznetsov et al., 2001). HSCs are multipotent adult stem cells that give rise to all the 
myeloid and lymphoid cells of the blood. They give rise to cell progenies that constitute 
the lympho-hematopoietic system, responsible for the cell-mediated immunity such as 
monocytes, macrophages, cytotoxic T cells or natural killer cells and adaptive immunity (B 
cells), or cells initiating clotting (platelets). HSCs can also be found in peripheral blood in 
adults (Kuznetsov et al., 2001) or in umbilical cord blood of newborns and are critical in 
the study of blood-related malignancies (Lee et al., 2004). The first report of adult stem 
16 
 
cell differentiation into cardiomyocytes and transplantation into infarcted mice heart was 
done by bone-marrow-derived hematopoietic stem cells (Leri et al., 2005). However, some 
other studies have not demonstrated the differentiation of haematopoietic progenitor cells 
into cardiomyocytes (Balsam et al., 2004; Murry et al., 2004).   
2.6.3 Mesenchymal Stem Cells (MSCs) 
 As described earlier, several progenitor cells can be found in bone marrow niche 
and one class of progenitor’s cells in BM is known as mesenchymal or stromal stem cell 
(MSCs). The term “MSC” is introduced by Caplan (1991). However, seminal studies by 
Friedenstein (1970), Owen (1988), Tavassoli and Crosby (1970) identified what was 
initially referred to as bone marrow-derived ‘mechanocytes’ or stromal fibroblasts. Bone 
marrow mesenchymal stem cell (BM-MSC) was first described by (Friedenstein et al., 
1966) around 40 years ago.  
 
2.6.3.1 Isolation and Characteristics of MSCs 
  The first and the most important characteristic of MSCs is their tendency. MSCs 
were originally isolated from bone marrow (BM) aspirate based on their tendency, which 
allow spindle-shaped or fibroblast- liked cells to adhere to a plastic substrate in the cell 
culture plate. In contrast, most other bone marrow derived cells, like the highly researched 
HSCs that also reside in the bone marrow, do not possess this plastic-adherence property 
(Friedenstein, 1995). MSCs display stable phenotype in long-term culture and retain the 
potential for adipogenic, chondrogenic and osteogenic lineage differentiation in vitro and 
they are typically involved in the healing of damaged tissues such as bone, cartilage, 
muscle, ligament, tendon, and stroma in vivo ( Pittenger et al., 1999; Psaltis et al., 2008).  
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 Although, there is a very small fraction of MSCs (0.001–0.01% ) in bone marrow, 
they can be isolated and expanded with high efficiency and induced to differentiate into 
multiple lineages under defined culture conditions (Pittenger et al., 1999). They have been 
isolated almost from every type of tissue, including peripheral blood (Kuznetsov et al., 
1997), umbilical cord blood (Lee et al., 2004), dental pulp (Gronthos et al., 2000), amniotic 
fluid (Anker et al., 2003), fetal blood (Noort et al., 2002), lung (Fan et al., 2005), liver 
(Campagnoli et al., 2001) adipose tissues (Zuk et al., 2002), intestine ( Bjerknes & Cheng, 
2006) and hair follicle (Amoh et al., 2005). 
  In experimental animals, bone marrow aspirates are normally taken from the tibias 
and femurs. In human marrow donors, they are often harvested from the superior iliac crest 
of the pelvis (Digirolamo et al., 1999; Barry & Murphy, 2004). Frequently, the marrow 
sample is subjected to fractionation via density gradient centrifugation and cultured in a 
medium such as Dulbecco’s modified Eagle’s medium (DMEM), containing 10-20% fetal 
bovine serum. Primary cultures are usually maintained for 16-21 days and are then 
detached by trypsinization, followed by sub-culturing (Pittenger et al., 1999; Barry, 2003).  
In the recent development of regenerative medicine, MSCs have been the favorite sources 
of stem cells for transplantation because of their potent differentiation capability, and also 
the accessibility and possible autologous transplantation to eliminate immuno-rejection ( 
Dezawa et al., 2004; Kolf et al., 2007). The unique immunophenotype characteristics of 
MSCs which coupled with powerful immunosuppressive activity have made MSCs as a 
leading candidate for allogeneic transplant (Sato et al., 2005; Krampera et al., 2006; 
Gimble et al., 2008). The potential of the putative functions for MSCs in regenerative 
medicine are such that hundreds of human trials involving MSCs are currently underway 
all across the world (Williams et al., 2011). However, despite the great interest, the MSCs 
remains enigmatic as both its identity and qualification as a true stem cell remains 
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uncertain and this uncertainty results from lack of universally defined cell surface markers 
to characterize the MSCs in the manner of the hematopoietic stem cell (Devine, 2002; 
Baksh et al., 2004; Rastegar et al., 2010).   
2.6.3.2 MSCs Marker  
  One of the obstacles in defining MSCs is that there are no immunophenotypic 
markers that are uniquely and specifically expressed by MSCs up to date (Rastegar et al., 
2010; Williams & Hare, 2011). Scientists have made many attempts to develop a cell-
surface antigen profile for the better purification and identification of MSCs. However, the 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy (ISCT) has came up with some criteria to define human MSC which is as follow: 
MSC must be plastic-adherent when maintained in standard culture condition; MSC must 
express CD105, CD73 and CD90 and lack of CD45, CD34, CD14, CD79, CD19 and HLA-
DR expressions; MSC must differentiate into osteoblasts, adipocytes and chondrocytes in 
vitro (Dominici et al., 2006). In general, MSCs do not express cell surface markers such as 
CD11b (an immune cell marker), CD31 (expressed on endothelial and hematopoietic 
cells), CD34 (the primitive hematopoietic stem cell marker), and CD45 (a marker for all 
hematopoietic cells) (Haynesworth et al., 1992; Majumdar et al., 2003).  
 On the other hand, cells from MSCs culture are known to be positive for the 
surface peptides SH2, SH3, SH4 (monoclonal antibodies), the surface receptors CD35 
(trans-membrane protein), CD73 (5'ectonucleotidase), CD90 (Thy1), CD123 (interleukin-3 
receptor) and CD117 (a hematopoietic stem/progenitor cell marker), CD271 (neurotrophic 
growth factor) and Stro-3-positive mesenchymal precursor cell (Kuçi et al., 2010). Other 
cell types such HSCs also express these markers. Thus, it would be preferable if there is 
truly a unique marker to identify the most immature and, therefore, the most highly potent 
19 
 
MSCs (Kuci et al., 2010; Kim & Ahn, 2012). In addition, with minor differences in 
expression patterns from one tissue source to another, all MSCs express embryonic cell 
markers such as Oct4, Nanog, and stage specific embryonic antigen-4 (SSEA-4) ( Gang et 
al 2007; Christensen, 2010). In order to further distinguish MSCs from HSCs, the cultured 
cells can be selected against the hematopoietic characteristic markers CD34, CD45 and 
CD14 (Haynesworth et al., 1992; Majumdar et al., 2003). However, since there is no 
currently known MSC-specific cell surface markers that exclusively identify MSCs;  
therefore, isolated MSC populations are still not entirely homogenous (Peister et al., 2004; 
Rastegar et al., 2010; Williams & Hare, 2011; Asumda, 2013).   
2.6.3.3 Differentiation Potential of Mesenchymal Stem Cells 
  Upon induction by specific compounds, cultured MSCs can differentiate into a 
variety of mature cell types (Figure 2.2). Friedenstein and his colleagues (1970) isolated 
first MSCs and differentiated them into bone and cartilage in vitro 40 years ago. Several 
groups have demonstrated that long-term cultured MSCs can be induced to differentiate 
into pancreatic (Lee et al., 2004), neural lineages (Woodbury et al., 2000), bone 
(Haynesworth et al., 1992), cartilage (Yoo et al., 1998), muscle (Wakitani et al., 1995), 
marrow stroma (Majumdar et al., 1998), tendon and ligament (Young et al., 1998), fat 
(Dennis et al., 1999), and a variety of other connective tissues (Studeny et al., 2004). 
  BMMSCs have been shown to ameliorate tissue damage and to improve function 
after myocardial infarction (Iso et al., 2007; Cho et al., 2011), lung injury (Ortiz et al., 
2007; Curley et al., 2012), kidney disease (Kunter et al., 2006; Alfarano et al., 2012), 
diabetes (Lee et al., 2006; Si et al., 2012), liver injury (Kanazawa et al., 2011; Zhao et al., 
2012) and neurological disorders (Edalatmanesh et al., 2011). Several studies have shown 
that involvement of BM-MSCs is a promising therapeutic option for the treatment of heart 
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disease (Orlic et al., 2003; Antonitsis et al., 2008; Garcia et al., 2008; Psaltis et al., 2008). 
Moreover, numerous studies have shown differentiation potential of MSCs have attracted 
significant attention to their possible role in elucidating differentiation pathways and 
promoting tissue engineering as gene vectors and immunomodulators in autoimmune 
diseases in recent years (Rastegar et al., 2010). From review of many reports, it can be 
finalized that MSCs have the potential to differentiate into several different mesenchymal 
lineages such as muscle, bone, cartilage, fat, tendon, and marrow stroma, upon induction 
by different compounds. It is discovered that under certain culturing conditions, MSCs can 
differentiate into mature, specialized cells other than those of the mesenchymal tissues, 
including cardiomyocytes. During differentiation of a stem cell into a mature cell, the cell 
changes its phenotype as it becomes committed to a certain function. The discovery of 
genes whose expression is changed along differentiation into a certain lineage may shed 
light on biological pathways associated with that specific differentiation process and its 
induction methods. For instance, studies have shown that during differentiation of MSC 
into cardiomyocyte, some cardiac specific genes such as myosin heavy chain (MHC), 
cardiac troponin T (cTnT), NKx2.5 and GATA4 become upregulated and expressed (Reik, 
2007). The transcription factor GATA4 is a critical regulator of cardiac gene expression, 
modulating cardiomyocyte differentiation and adaptive responses of the adult heart (Oka et 
al., 2007; Heineke et al., 2007). GATA4 is also expressed in the adult heart where it is 
thought to function as a key transcriptional regulator of numerous cardiac genes including 
atrial natriuretic factor (ANF), b-type natriuretic peptide (BNP), MHC, and many others. 
MHC and cTnT are the two major contractile proteins which playing important roles in the 
regulation of skeletal and cardiac muscle in most of the vertebrates and mammals heart 
(Willie et al., 1999).  
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Figure 2.2: Differentiation potential of bone marrow-derived mesenchymal stem cells. 
They  are capable of replicating and having its progeny differentiate to produce  bone, 
cartilage, muscle, marrow stroma, tendon/ligament, and other connective tissues (Caplan & 
Dennis, 2006). 
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2.7 DNA Methylation:  
 DNA methylation constitutes major mechanisms that are responsible for epigenetic 
regulation of gene expression during development and differentiation (Li, 2002; Cedar & 
Bergman, 2009). DNA methylation is an important epigenetic mechanism, which has been 
reported to be involved in gene expression, chromosome inactivation, genomic imprinting 
and endogenic gene silencing (Sulewska et al., 2007). DNA methylation is also important 
in maintaining pluripotency and self- renewal of stem cells. To maintain pluripotency of 
cells, genes are usually activated during hypomethylation and genes that are associated 
with differentiation are repressed by hypermethylation (Fouse et al., 2008).  
 The most well studied and widely used drugs to inhibit DNA cytosine methylation 
and reactivate silenced is 5-azacytidine (Taylor & Jones, 1980; Harris, 1982). Zebularine is 
also another DNA methyltransferase inhibitor, which was developed as a more stable and 
less toxic drug recently (Yoo et al., 2004). Zebularine and 5-azacytidine (Figure 2.3) were 
originally developed as cancer chemotherapeutic agents (Vesely & Cihak, 1975) and are 
powerful inducers of genes silenced by DNA methylation (Jones, 1985). In this study, 
these two synthetic compounds were used for induction of MSCs into cardiac-like cells. 
2.8 5-azacytidine and Zebularine as Cardiomyogenic Inducer 
     One of the most important and well characterized DNA demethylating agents is 
5-azacytidine (Jüttermann et al., 1994; Naeem et al., 2013). DNA methylation inhibitors 
such as 5-azacytidine (5-aza-CR) and its deoxy analog, 5-Aza-2’deoxycytidine (5-Aza-
CdR) have been studied for decades. However, both drugs are toxic in vitro and in vivo, 
and have been difficult to administer due to their low stability in aqueous solution (Taylor 
& Jones, 1982). 5-azacytidine incorporates into DNA and forms a covalent irreversible 
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complex with DNA methyltransferase (DNMT) preventing the enzyme from methylating 
position 5 of cytosines clustered in regulatory CpG islands (Cheng et al., 2003). 
 Several studies reported BM-MSCs can be induced with 5-azacytidine treatment to 
express cardiac-specific markers and exhibit spontaneous beating and measurable action 
potential, consistent with a myocyte lineage ( Toma, 2002; Xu et al., 2004; Dimarakis et 
al., 2006; Ye et al., 2006; Antonitsis et al., 2007; Naeem et al., 2013). However, 
cardiogenic differentiation of stem cells with the use of 5-azacytidine is still controversial. 
Zhang et al. (2007) reported that the cardiomyogenic differentiation potential of bone 
marrow mesencymal stem cells was passage-restricted. Their result showed that treatment 
of mesenchymal stem cells with 5-azacytidine expressed cardiac specific markers and 
myotubes formation at only passage 4 (P4). In addition, Liu et al. (2003) reported that 
when cells are only immortalized, 5-azacytidine can induce rat bone marrow stromal cells 
to differentiate into cardiomyogenic cells.  
 Zebularine, a cytidine analog containing a 2-pyrimidinone ring, is another novel 
DNA methyltransferase (DNMT) inhibitor, which was developed as a more stable and less 
toxic drug compare to 5-azacytidine (Yoo et al., 2004). Zebularine was originally 
developed as a cytidine deaminase inhibitor. It lacks an amino group at position 4 of the 
pyrimidine ring (Kim et al., 1986; Driscoll et al., 1991). Despite of many reports of using 
5-azacytidine as MSCs inducer, there are a few studies which reported the potential of 
zebularine as cardiogenic inducer. The ability of zebularine to inhibit DNA methylation 
was widely studied in microbial system, cancer therapy, as well as mammalian cell lines 
(Irelan & Selker, 1997; Cheng et al., 2003). Cheng and colleagues (2003) reported that 
both zebularine and 5-azacytidine induced the expression of the myogenic phenotype in 
mouse embryonic fibroblast cells and inhibited the methylation of specific loci in both the  
mouse CII-d and human p16 promoter. Naeem and his colleagues (2013) also stated that  
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zebularine can be used as a new candidate for cardiogenic inducer. However they reported 
that the extent of muscle cell formation in cultures treated with zebularine was less than 
that induced by 5-azacytidine. More studies need to be done, in order to investigate and 
explore more potential of these two compounds. In this study, the cardiomyogenic  
differentiation potential of BM-MSCs in response to 5-azacytidine and zebularine 
treatment was investigated. 
 
 
 Figure 2.3: Structures of 5-azacytidine and zebularine: 5-azacytidine contains a nitrogen 
in position 5 and zebularine contains a 2-(1H) pyrimidinone ring (Taylor and Jones, 1982; 
Zhou et al., 2002). 
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2.9 Therapeutic Uses of MSCs  
    Several possible therapeutic functions exist for MSCs. First, they may directly 
participate the cell repopulation via expansion and differentiation. Disease caused by 
physical or chemical damage may be treated and cured by directing the differentiation of a 
patient’s own stem cells into the depleted cell types and introducing them into the affected 
tissue (Christensen, 2010). The hypothesis that MSCs could reconstitute a population of 
stem cells in adipose, bone, or cartilaginous tissues has been put forward for many years 
(Prockop, 1997), and continually investigated till now (Mareddy et al., 2007). Moreover, 
as stated previously, MSCs are under investigation for direct repair of many other tissues 
such as heart, kidney, brain and skin. 
 A second possible role of MSCs is as a vessel for delivering a therapeutic 
transgene. The dysfunctional alleles that may be responsible for a disease can be 
circumvented by the insertion of a functional gene into the patient’s stem cells, followed 
by transplantation into an appropriate tissue where they can propagate and produce the 
therapeutic gene products (Reiser et al., 2005).  
 Transplanted MSCs have been reported to stably reside in severa l tissue types 
including cardiac (Kraitchman et al., 2005), bone (Lee et al., 2001), and neural tissues 
(Torrente et al., 2008). Because of MSCs ability to migrate, they have been shown to be an 
effective and important therapeutic agent to fight the tumor glioblastoma multiforme 
(GBM). MSCs engineered to express tumor necrosis factor apoptosis ligand (TRAIL) were 
shown to migrate toward GBM cells. There, they remained undifferentiated and non-
expansive, and stably expressing and secreting TRAIL, effectively reducing the tumor 
burden and increasing survival time in a mouse model (Sasportas et al., 2009). 
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 The third therapeutic role for MSCs is as an immune system modulator. Several 
studies have shown that allogeneic transplantation of MSCs does not appear to induce 
immune response (Devine et al., 2001; Le et al., 2004; Rastegar et al., 2010). As discussed 
earlier, MSCs produce an immunomodulatory effect by interacting with both innate and 
adaptive immune cells. MSCs have been shown to suppress most of the innate immune 
cells such as neutrophils, dendritic cells (DCs), natural killer cells, eosinophils, mast cells, 
and macrophages (Rastegar et al., 2010). MSCs have also shown to suppress adaptive 
immune cells such as T and B lymphocytes (T-cell, B-cell) proliferation in a mixed 
lymphocyte culture (Di et al., 2002; Aggarwal & Pittenger, 2005; Christensen, 2010; 
Rastegar et al., 2010). Suppression of lymphocyte proliferation is mediated through 
cytokines released by MSCs that equally suppress the proliferation of cytotoxic and helper 
T cells (Di et al., 2002). Overall, the possibility of transplanting allogeneic MSCs, 
removing the need to harvest cells from a patient if it may cause undue risk. Also, 
expansion of MSCs can take place prior to need, and universal donors may be utilized for 
many patients. Importantly, MSCs harvested from adult rhesus monkey bone marrow have 
shown decreased potential for self-replication and differentiation when compared to MSCs 
from younger age groups (Lee et al., 2006; Hacia et al., 2008). Therefore, future 
therapeutic approaches for adult patients may prove to be more effective when utilizing 
allogeneic cells from younger donors (Gracia et al., 2008).   
 A fourth possibility for MSCs in tissue repair is an indirect role in support of other 
cell types. MSCs are known to support hematopoiesis in bone marrow by acting as part of 
the stroma and allogeneic. MSC transplants have been shown to enhance engraftment of 
HSCs (Almeida et al., 1999). MSCs supply physical support and cytochemical direction by 
producing growth factors and cytokines, likely providing the essential cues for cell 
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proliferation and differentiation (Ball et al., 2008). MSCs given to patients who 
experienced tissue toxicity after receiving HSC transplants have been shown to aid in 
clearing severe haemorrhagic cystitis, pneumo-mediastinum, as well as diverticulitis and 
peritonitis caused by steroid-resistant graft versus host disease (GVHD) (Ringden et al., 
2007). There is a similar role for those MSCs found to reside in other tissues undergoing 
repair and re-growth. MSCs have been shown as home to areas of hypoxia and cause rapid 
revascularization after tissue injury (Rosova et al., 2009). This ability is particularly 
important for the treatment of a myocardial infarction (MI). Ischemic tissue regeneration 
studies utilizing MSCs have included stroke models (Li et al., 2005), skeletal muscle 
ischemia (Nakagami et al., 2005; Kim et al., 2006), and a MI model (Tang et al., 2006). 
The utilization of MSCs for cardiac repair is one area of regenerative medicine where all of 
these cells’ putative therapeutic capabilities have been explored.  
2.10 Therapeutic Potential of MSCs for Heart Diseases: 
 Heart diseases including myocardial infarction (MI) (heart attack), coronary and 
ischemic heart diseases are leading cause of morbidity and mortality in the world (Psaltis 
et al., 2008; Mendis et al., 2011). These acute and chronic heart diseases endanger millions 
of peoples in developed and developing countries and are predicted to be the leading cause 
of death by 2030 (Humphreys, 2011; Elnakish et al., 2012 ).  
    Mutipotent adult MSCs have shown that to have great potential as treatment for 
many diseases and clinical applications of tissue regeneration, including myocardial 
regeneration (Qian et al., 2012). Several researches including preclinical and clinical 
studies have suggested that isolated or cultured  bone marrow derived stem cells can be 
used for treatment of injured cardiac (Toma et al, 2002; Williams et al., 2011).  
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 Several preclinical studies on large animal species such as swine (Shake et al., 
2002; Quevedo et al., 2009), sheep (Hamamoto et al., 2009), and dogs (Silva et al., 2005; 
Perin et al., 2008) have been used to investigate the effects of MSC therapy for heart 
diseases particularly myocardial infarction (MI). For instance, a study by Quevedo et al. 
(2009) showed BM-MSCs exhibit the ability to differentiate into cardiomyocytes, smooth 
muscle cells, and endothelium in a swine model of chronic ischemic cardiomyopathy. 
Another study by Miyahara et al. (2006) on rats showed MSCs transplantation improve 
cardiac function and also significantly increase survival rates in post-MI. To note, there are 
some methods for delivering stem cells to the heart including peripheral intravenous 
infusion, direct surgical injection during open heart surgery, or via a catheter-based 
intracoronary infusion and retrograde coronary venous infusion (reviewed by Williams & 
Hare, 2011). Studies have shown intravenous fusion of MSCs is the easiest and most 
practical method for delivery, though the MSCs must travel through the pulmonary 
circulation, where entrapment of cells is a concern (Barbash et al., 2003). However, many 
studies showed low retention of stem cells in the heart by any mentioned delivery route. 
Despite low retention of stem cells in the heart, preclinical results of MSC therapy have 
shown highly promising results for cardiac diseases. Based on the review by Williams and 
Hare (2011), there was a significant improvement of left ventricle function, reduction of 
scar size and increscent of myocardial tissue perfusion in post-MI large animal models,  
regardless of delivery method or species.  
 MSC therapy for acute MI and ischemic cardiomyopathy also showed safe result 
and has favorable effects on cardiac structure and function based on early-phase clinical 
trial data (Chen et al., 2004; Williams et al., 2011). Phase I/II clinical data have reported 
using intravenous therapy (Hare et al., 2009), intracoronary infusion (Chen et al., 2004), 
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and intramyocardial injection (Williams et al., 2011). Many other studies have also shown 
that use of bone marrow- derived MSCs (BM-MSCs) is a promising therapeutic option for 
the treatment of heart disease (Obradovic et al., 2004; Miyahara et al., 2006; Hare et al., 
2009; Williams et al., 2011). Stamm and colleagues (2003) demonstrated the delivery of 
bone marrow cells into the infarct zone in patients following MI.  
 In a randomized, double-blinded study, patient receiving an IV infusion of MSCs 
post-MI demonstrated significant enhancement in cardiovascular function (Hare et al., 
2009). The similar therapeutic benefit was also reported in patients receiving intracoronary 
MSC administration compared to placebo (Dill et al., 2009). The result of this treatment 
was a dramatic improvement in global heart function which indicates that stem cell therapy 
can be useful in treating coronary artery disease. In summary, despite of the great potential 
of MSCs for heart disease’s treatment,  novel strategies and methods are needed to be 
developed for delivery and enhancement of stem cell retention in the heart. The exact 
mechanism action of MSCs differentiation into cardiomyocytes is still poorly understood 
and unresolved (Quevedo et al., 2009; Hatzistergos et al., 2010).  
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CHAPTER 3 
MATERIALS & METHODS 
 
All lab works were carried out in the International Center for Chemical and Biological 
Sciences (ICCBS), University of Karachi, Pakistan, in the Stem Cell Lab Headed by 
Assoc. Prof. Dr. Asmat Saleem. Procedures for sacrificing the animals were performed in 
accordance with the guidelines for animal experimentation by the ICCBS’s Institutional 
Animal Care and Use Committee (IACUC). 
3.1 Chemicals and Materials  
All chemicals, apparatus and materials used in this study are listed in Appendix A. The 
details of different chemical solutions preparations are given in Appendix B. 
3.2 Bone Marrow Sample 
 Bone marrow sample for isolation of mesenchymal stem cells (BM-MSCs) were obtained 
from adult 200-300 grams Sprague Dawley (SD) rats. Anesthetized SD rats were sacrificed 
and tibia and femur bones were dissected out, and subsequently cleaned from muscle and 
connective tissues. The bones were then placed in a sterilized petri dish containing sterile 
phosphate buffered saline (PBS) (Sigma, USA) before being transferred to the cell culture 
room for isolation. The culturing of bone marrow mesenchymal stem cells (BM-MSCs) 
was subsequently carried out in cell culture room (Figure 3.1).  
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Figure 3.1: Bone marrow isolation from Sprague Dawley (SD) rats. Anesthetised SD rat 
was sacrificed and tibia and femur bones were dissected out (A and B) and cleaned from 
muscle and connective tissue (C). The bones were then placed in a sterilized petri dish 
containing sterile phosphate buffered saline (PBS) before being transferred to the cell 
culture room. The marrow cavities of these bones were flushed by using a 1ml disposable 
syringe with a 26-gauge needle with complete medium (D).  
 
 
A 
D C 
B 
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3.3 Isolation, Expansion and Maintenance of BM-MSCs 
BM-MSCs were isolated from fresh bone marrow samples as follows: The marrow cavities 
of the bones were flushed by using a 1 ml disposable syringe with a 26-gauge needle with 
complete Dulbecco’s Modified  Eagle Medium (DMEM) (Figure 3.1). DMEM contained 
high glucose, and was supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) 
penicillin-streptomycin, 1mM sodium pyruvate and 4mM L-glutamine (Gibco, USA). 
Isolated cells were then plated at a density of 5×106, 2×107 cells per T75 flasks and 
incubated in a humidified atmosphere of 5% CO2 at 3   C for 7 days. This culture is termed 
as the primary culture (Passage 0 or P0 cells).   
3.4 Changing the Culture Medium 
As described earlier in the literature review, MSCs have the ability to adhere to the plastic 
surface of the flask. Non-adherent hematopoietic cells were removed using frequent 
medium change. During the expansion and maintenance of MSCs, the medium was 
replaced three times per week until almost complete removal of dead and hematopoietic 
cells and 70-80% confluence of MSCs, which took between 16 to 20 days. Flasks were 
kept back in the CO2 incubator, which has a humidified environment with 5% CO2 at 37
oC. 
3.5 Sub-culturing /Passaging 
After 70-80% confluence of MSCs which took around 16-20 days, MSCs were sub-
cultured. Initially, Medium was aspirated from the tissue culture flask. Cells were washed 
2-3 times with 4-6ml PBS by swirling the flask carefully so that all medium was removed 
from the flask. 10X (2.5%) trypsin-EDTA (Gibco, USA) was diluted to 1X (0.25%) 
concentration using PBS, and 3-4ml 1X trypsin-EDTA was then added to the flask. The 
flask was swirled to distribute trypsin-EDTA evenly and incubated for 5 minutes at 37oC. 
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The cells were observed under phase contrast microscope (Nikon, Japan) for detachment 
from the surface of the flask. After complete detachment, approximately 2-3ml complete 
DMEM was added into the flask to stop the reaction. The dissociated cell suspension was 
transferred into 15 ml falcon tube and centrifuged at 1200g for 8 minutes (Eppendorf, 
Germany). The supernatant was then discarded and approximately 1ml fresh medium was 
added to the pellet. Pelleted cells were mixed well and equally distributed in two 75cm2  
flasks (Passage 1 or P1). So basically, one flask of MSCs was divided to two flasks. The 
flasks were labeled and incubated at 37oC in the incubator containing 5% CO2.  For all 
experiments passage 1 or passage 2 cells were used. 
 
3.6 Characterization of Mesenchymal Stem Cell 
3.6.1 Immunocytochemistry 
Passage 1 (P1) MSCs, were grown in chambered glass slides (Iwaki, Japan) using 10,000 
cells/200µl per well and incubated in a humidified environment at 37oC in the incubator 
containing 5% CO2. On the next day, the medium was removed from the chambered slides 
and washed 2-3 times with 0.1% PBS. Cells were fixed by adding 250-300µl 4% 
paraformaldehyde (PFA) in PBS and were permeablized with 0.1% tritonX-100 (250µl) in 
PBS for 20 minutes at room temperature. Cells were again washed with PBS three times 
for 3-5 minutes. Cultures were blocked by blocking solution (250µl), which contained 2% 
bovine serum albumin (BSA); 2% goat serum and either 0.2% Nonidet P40 or 0.1% Tween 
20) at 37oC to block non-specific binding sites (Table 3.1).  
Next, 2.5 µl Primary antibodies (Bioscience, USA) were incubated overnight at 4ºC against 
the following proteins: CD44, CD117 (positive marker, 1:100), CD34 (negative marker, 
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1:100). Negative controls were obtained by omission of the primary antibody. Next day, 
cells were washed three times with PBS for 5 minutes and then incubated with secondary 
antibody conjugated to either Alexa Fluor 488, or Alexa Fluor 568 (1:200; Molecular 
Probes) for 1 hour at room temperature. The solution was then discarded and washed three 
times with PBS for 5 minutes. Nuclei of MSC cells were counter stained with DAPI to 
preserve fluorescence. MSCs were washed five times with PBS for 5 minutes and finally 
rinsed with distilled water for 1 minute. Finally MSC cells were mounted with mounting 
medium (Merck, Germany) and were examined under fluorescent microscope (Nikon, 
Japan).    
 
                    Table 3.1 Blocking solution preparation for immunocytochemistry  
 Components                                                 volume  
        2%  BSA*                                                      0.02 g 
2%  goat serum                                               200µL 
0.1% Tween 20                                                   1µL 
Distilled water                                               1000µL 
                     
                         * BSA: bovine serum albumin 
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3.6.2 Flow Cytometry (FACS- Fluorescence-activated cell sorting) 
Flow cytometry analyses (FACS) were performed in the presence of cell surface markers 
on BM-MSCs by using Flow cytometer (FACS Calibur, Becton Dickinson, USA). Cells 
were stained for the expression of CD44 (positive marker), CD45 (negative marker), blank 
control (no antibodies) and negative control (only secondary antibody) using Goat anti-
mouse antibodies coupled with flurochromes as following details:  
Details regarding preparation of flow cytometry solutions are listed in Table 3.2. BM-
MSCs were grown in tissue culture flask and washed two times with PBS. The cells were 
detached by adding 3-5 ml cell dissociation buffer, enzyme free; Hank’s based (Gibco, 
USA). It was then incubated at 37oC for 30-45 minutes. The dissociated cell suspension 
was transferred into a 15 ml falcon tube and centrifuged at 800 rpm for 8 minutes at 4oC. 
Supernatant was removed and 400 µl cold FACS solution (PBS containing 1% BSA, 1mM 
EDTA and 0.1% sodium azide) was added to the pellet. 400 µl of cell suspension were 
equally divided into four non pyrogenic polystyrene FACS tubes (to be used for different 
primary antibodies) for which each tube contained 100 µl cell suspensions. 5 µl blocking 
solution (PBS containing 1% BSA) was added into each tube, mixed well by vortexing and 
incubated at room temperature for 2 minutes. The cells were then incubated at 4°C for 30 
minutes in dark with primary antibodies against CD44 and CD45 at 1:40 dilution. Cells 
were washed twice with a 2ml FACS solution, vortexed and centrifuged at 800 rpm for 10 
minutes. The cells were then treated with Alexa Fluor 546 goat-anti mouse secondary 
antibodies at 1:500 dilution (100 µl for each tube), vortexed and incubated in dark for 30 
minutes on ice. Cells were again washed twice with 2 ml FACS solution, vortexed and 
centrifuged at 800 rpm for 5 minutes. Finally 500 µl FACS solution was added to each 
tube and mixed well and analyzed through flowcytometer. FSC was selected as the 
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threshold parameter and the threshold was set to a value of 52 which eliminated small 
debris. Data was evaluated using BD Cell Quest Pro software. 
 
        Table 3.2: Preparation of FACS solution, Blocking solution and PBS 1X 
      FACS solution Blocking solution           PBS 1X 
   
  0.5g of 1% BSA 
 0.0146g of 1 mM EDTA 
 0.05g of 0.1% sodium            
azide 
   10 ml of 1% BSA 
 
        8 g of NaCl 
        0.2g of KCI 
       1.15g of Na2 HPO4 
       0.2g of KH2PO4 
 
         BSA: bovine serum albumin 
         KCI: potassium chloride 
         KH2PO4: Potassium dihydrogen phosphate 
         NaCl: sodium chloride 
         Na2 HPO4: sodium hydrogen phosphate 
         PBS: phosphate buffered saline 
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3.7 Differentiation of BM-MSCs into Cardiomyocytes-like Cells 
3.7.1 Treatment of MSCs with 5-Azacytidine and Zebularine  
Passage 1 (P1) MSCs and 3µM optimized concentration of 5-azacytidine and zebularine 
were used in this experiment following protocol established by Naeem and colleagues 
(2013). MSCs were divided into three separate groups as follow: (1) untreated control, (2) 
treated with 3 µM of 5-azacytidine, (3) treated with 3 µM of zebularine. Details regarding 
preparation of stock and working solutions of 5-azacytidine, zebularine are given in 
Appendix B. After 70-80% confluence of passage 1 (P1) MSCs, which may take around 
16-20 days, old media was discarded. Subsequently, 3µM of each compound solution was 
added directly in DMEM, which was then added to the tissue culture flask and incubated at 
37oC in an incubator containing 5% CO2. After overnight incubation (24 hour), cells were 
washed twice with PBS and medium was replaced with the complete culture DMEM 
medium.  
3.7.2 Expression Analysis of Cardiac Specific mRNA 
3.7.2.1 Isolation of RNA from Treated and Untreated MSCs 
Total RNA was extracted from normal and treated BM-MSCs by spin method according to 
the manufacturer’s instructions (Promega, USA). After 80-90% confluence of cells, the 
medium was discarded from the flasks. Cells were washed twice with 5-10ml of PBS. 
Next, 3ml of trypsin (0.25%) (v/v) was added to the flasks and incubated for 5-7 minutes at 
a 37°C using air jacketed CO2 incubator. After the complete detachment of cells, 7-8ml of 
complete DMEM was added to the flask. The dissociated cell suspension was transferred 
to a 15 ml falcon tube and centrifuged at 1000 rpm for 5 minutes to pellet the cells.  
38 
 
Supernatant was removed and 600µl of RNA lysis buffer (RLT) with freshly added β 
mercaptoethanol (βME) (10 µl per 1ml buffer RLT) were added to disrupt the pellet. Cell 
lysate was transferred directly onto a QIA shredder spin column placed in a 2ml collection 
tube and centrifuged at maximum speed. A series of steps followed: 600 µl of 70% ethanol 
was added to the lysate and mixed well by pipetting; 700µl of this mixture was applied to 
the RNeasy mini column placed in a 2ml collection tube, centrifuged at 10500g for 15 
Seconds. 700 µl buffer RNA Wash solution (RW1) was added to RNeasy column and 
centrifuged at 10500g for 15 Seconds. Flow through was again discarded along with the 
collection tube. RNeasy column was transferred to a new collection tube. 500 µl buffer 
RPE was added onto the RNeasy column and centrifuged at 10500g for 15 seconds. 
Similarly, Flow through was discarded. Another 500 µl buffer RPE was added onto the 
RNeasy column and centrifuged at 10500g for 2 minutes to dry the RNeasy silica gel 
membrane. Flow through was again discarded. RNeasy column was then placed in a new 
2ml collection tube and centrifuged at full speed for 1 minute. Finally, RNeasy column 
was transferred to a new 2ml collection tube. An amount of 50 µl RNase-free water was 
added directly onto the RNeasy silica gel membrane to elute the RNA. The eluted RNA 
was stored at -20˚C till further steps in the experiments. 
3.7.2.2 Quantitative Measurement of RNA’s Concentration  
The purity of the total RNA was assessed spectrophotometrically at 260 and 280 nm, with 
an A260: A280 ratio of 1.8–2.0 considered acceptable. RNA was diluted (1:200) in deionized 
water and deionized water was used as blank. The ratio A260/A280 was measured to check 
the purity of RNA samples.  
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Concentration of RNA was calculated using the following formula: 
 
             [RNA] µg/ml = OD260 /OD280 x Dilution Factor x *40.0 
* The absorbance of 1 unit is equivalent to 40 µg of RNA per ml  
Total RNA yield was calculated by the following formula: 
      Total yield = concentration of RNA sample x volume of sample in milliliters  
 
3.7.2.3 cDNA Synthesis  
First strand cDNA was synthesized by using first Strand cDNA Synthesis Kit (Invitrogen, 
USA) according to the manufacturer’s instructions. 1µg of total RNA was subjected to 
cDNA synthesis by using 50µM oligo (dT)18 primer. The amount of RNA that is 
equivalent to 1 µg was then taken in a 0.2 ml tube. 
 RNA/ primer mixture was next prepared (Table3. 3). The mixture of RNA/Primer was 
adjusted by adding Diethylpyrocarbonate (DEPC) treated water to 10 µl and incubated at 
65oC for 5 minutes and placed on ice for 1 minute. The cDNA synthesis mixture was also 
prepared separately (Table 3.4). To the RNA/primer mixture, 10µl of cDNA synthesis 
mixture was added and incubated at 50oC for 50 minutes. The reaction was terminated at 
85oC for 5 minutes and chilled on ice. The cDNA synthesis mixture was stored at -20oC. 
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                          Table 3.3: Components used in RNA/primer mixture 
Components                                                       volume  
Total RNA                       1µg 
50 µM Oligo (dT) 20 primer                       1 µl 
10 mM dNTP mix                       1 µl 
DEPC treated water                                    up to 10 µl 
 
                               DEPC: Diethylpyrocarbonate  
                               dNTP: Deoxynucleotide mix 
 
 
                         Table 3.4: Components of cDNA synthesis mixture  
Components                                                           volume  
10 X buffer                                                             2 µl 
25 mM MgCl2                                                             4 µl 
0.1 M DTT                                                             2 µl 
RNAse OUT (40 U/ µl)                                     1 µl 
Superscript TM III RT (200 U/ µl)                            1 µl 
 
                        DTT: Dithiothreitol  
                        MgCl2 : Magnesium chloride 
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3.7.2.4 Amplification by Reverse Transcriptase (RT) PCR 
Transcriptional expression of glycer aldehyde-3-phosphate dehydrogenase (GAPDH), 
myocardium cardiac alpha heavy chain (CAMHC), Cardiac troponin-T (cTnT), and cardiac 
transcription factors (GATA-4) genes were determined by reverse transcriptase (RT) PCR 
according to the manufacturer’s instructions (Thermo Scientific, USA).   
Primers were synthesized by Integrated DNA Technologies (IDT) and designed by using 
the primer3 design program (http://frodo.wi.mit.edu/primer3). Information on the primers 
details is summarized in Table 3.6. All primers were reconstituted in 10mM Tris-EDTA 
buffer (TE buffer; pH 8.0) prepared from (10X) 1M stock.      
The volume of the TE buffer was calculated for 100µM stock of primer as follows: 
Volume of TE buffer in ml = (x)* µMoles x 1000ml /100µMoles 
 
           * (x) µMoles = Amount of oligo in µg/ molecular weight 
 
cDNA (1µg) was amplified by using Fermentas Life Science’s PCR kit (Thermo Scientific, 
USA) according to the manufacturer’s instructions and PCR mixture was prepared in 
RNase/DNase free 0.2ml microcentrifuge tube on ice. 50µl reaction volume was prepared 
and the components were added in described in Table 3.5.  
 All the components were mixed, briefly centrifuged and the microcentrifuge tubes were 
placed in Thermal Cycler (Eppendorf, Germany) for amplification. Rat glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) primer was used as an internal standard in all 
experiments. Reverse transcription reaction products were denatured for 1 minutes at 94°C, 
followed by 35 cycles of amplification: denaturation at 94°C (1 minute), annealing at 50-
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60°C (1 minute), and extension at 72°C (1 minute) and a final extension at 72°C for 10  
minutes. The amplified products were stored at -20oC. 
 
 Table 3.5: Components used in PCR mixture  
Components            Amount        Final concentration  
      Q solution      10 µl 
10X PCR buffer containing MgCl2              5 µl             1X, 1.5mM MgCl2 
10mM dNTP mix       1 µl             0.2 mM 
Forward primer (100µM)      1 µl             2 µM 
Reverse primer (100µM)      1 µl             2 µM 
cDNA                  1 µg             <0.5 µg/50 µl 
Taq DNA polymerase (5U/µl)              0.5 µl              0.05 unit 
DEPC treated water                       29.5 µl 
Final volume                50 µl 
 
 
DEPC:  Diethylpyrocarbonate  
dNTP: Deoxynucleotide mix 
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     Table 3.6: summary of primers involved in RT-PCR experiments 
  
Gene 
PCR Primer 
Accession # Primer Sequence (5’-3’) 
 
Annealing 
Temperature 
(°C) 
Product size 
(bp) 
     
 
GAPDH  (F) 
GAPDH  (R) 
 
     BC09593 
 
GGAAAGCTGTGGCGTGATGG 
GTAGGCCATGAGGTCCACCA 
 
60 
 
414 
 
       cTnT (F) 
       cTnT (R) 
 
NM_012676 
 
 
    TTCGACCTGCAGGAAAAGTT 
      GTGCCTGGCAAGACCTAGAG 
 
57 
 
206 
 
 
GATA-4 (F) 
GATA-4 (R) 
 
NM_144730 
 
      TCTCACTATGGGCACAGCAG 
      CCGAGCAGGAATTTGAAGAG 
 
60 
 
245 
 
CAMHC (F) 
CAMHC (R) 
 
       X15938 
 
 
     TGATGACTCCGAGGAGCTTT 
       TGACACAGACCCTTGAGCAG 
 
57 
 
234 
     
 
 CAMHC: alpha myosin heavy chain 
cTnT: cardiac-specific troponin T 
GAPDH: glyceraldehyde phosphate dehydrogenase 
GATA-4: cardiac transcription factor 
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3.7.2.5 Agarose Gel Electrophoresis 
The amplified products were separated using 1% (w/v) agarose gel electrophoresis. Details 
regarding preparation of agarose gel and TBE buffer preparations are presented in 
Appendix B. One fifth of each PCR product was electrophoretically resolved on 1% 
agarose gel containing 1.5µl of 0.3µg/ml ethidium bromide.  
To start, 0.5gm agarose was dissolved in 10ml 5X TBE buffers, by heating the mixture in 
microwave oven for 1 minute. The solution was allowed to cool approximately to 60°C. 
1.5µl ethidium bromide was added and swirled gently. The gel was poured into the 
horizontal gel casting unit and allowed to polymerize for approximately 30 to 40 minutes. 
The tank was filled with 5X TBE buffer before. 10 µl DNA ladder and PCR products were 
loaded into the wells.  
3.7.2.6 Densitometry and Statistical Analysis  
Densitometry analysis was performed to measure the integrated density value (IDV) of 
each gene. The IDV of each band was compared with the corresponding GAPDH band, 
which was used to normalize the level of mRNA. The related information regarding 
densitometry was obtained by gel documentation system (Alpha Innotech, USA).  Data 
obtained were presented as mean ± standard error of the mean (SEM) and calculated using 
Microsoft Excel. Statistical significance (*p<0.05) was determined by using SPSS 
software and data were subjected to t-test to determine significant differences in gene 
expression level between differentiated and undifferentiated MSCs.  
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CHAPTER 4 
RESULTS 
 
4.1 Identification and Characterization of BM- MSCs 
4.1.1 Characteristics of Isolated and in Vitro BM-MSCs  
Bone marrow mesenchymal stem cells (BM-MSCs) were isolated from the tibia and femur 
of adult Sprague Dawley (SD) rats and cultured according to the adhesive property of 
mesenchymal stem cells (MSC) as described by Peister et al. (2004) and  Soleimani and 
Nadri (2009). When isolated BM-MSCs were seeded in culture flask, initially roundish or 
polygonal cell types appeared in bone marrow dissociates culture, which was a mixture of 
MSCs and non-adherent cell populations such as hematopoietic stem cells (HSCs). The 
HSCs were removed after frequent changing the culture medium. After 2-3 days, MSCs 
adhered to the wall in small quantity and scattered about showing spindle-shaped or 
fibroblast- liked morphology as previously reported by (Colter et al., 2001; Peister et al., 
2004; Soleimani & Naderi, 2009) (Figure 4.1). This result showed that bone marrow 
heterogeneity can be broken down in culture by prolonged growth and in a time dependent 
manner, resulting in distinct morphology such as fibroblast- liked phenotypes. Along with 
morphological characteristics, reverse transcriptase (RT) PCR, flow cytometry and 
immunostaining were also performed to confirm BM-MSCs which will be explained in the 
next sections.  
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 Figure 4.1: Morphology of undifferentiated BM-MSCs. BM-MSCs exhibited fibroblast-
liked morphology with their characteristic property of attaching to plastic culture dishes.  
At passage 0(P0), MSCs appeared as a mixture of small or spindle shaped cells (A and B). 
As MSC cells reached 70-80% confluence within 16-20 days, homogenous population of 
cells with uniform fibroblast- liked morphology was observed (C) and (D).  
  
 
 
 
 
 
(D) X200 
(A)X100 (B)X100 
(C)X100 
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4.1.2 Molecular Analysis of BM-MSCs 
Molecular analysis was initially performed to validate the expression of glyceraldehyde 
phosphate dehydrogenase (GAPDH) in MSCs. GAPDH is a housekeeping gene, which has 
always been activated by all mammalian cells whether differentiated or undifferentiated. 
The total RNA was extracted from the first passage of MSCs and was subjected to RT-PCR 
analysis (Figure 4.2).  Expression of GAPDH which served as an internal control was 
detected and amplicon (414 bp) was observed in untreated BM-MSCs indicating GAPDH 
remains activated in untreated MSCs. 
 
 
Figure 4.2: RT-PCR expression of GAPDH in undifferentiated BM-MSCs:  GAPDH as an 
internal control was detected in undifferentiated BM-MSCs. 
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4.1.3 Immunocytochemistry Analysis of BM-MSCs  
 In order to further distinguish mesenchymal stem cells from hematopoietic  stem 
cells, immunocytochemistry and flow cytometry were used to determine the presence of 
cell specific surface markers on MSCs. MSCs were first characterized for the positive 
presence of CD44, CD117 and negative presence of CD34 by immunocytochemistry. MSC 
cells were also treated only with secondary antibody (negative control). DAPI indicated the 
nucleus and merged indicated the positive or negative reactivity of marker proteins in 
immunocytochemistry analysis. Secondary antibodies employed were Alexa fluor 546 
(red) conjugated IgGs.  
 Immunocytochemistry analysis revealed that expression of cells surface marker 
were negative when cells treated only with secondary antibodies (negative control), 
indicating that in the absence of primary antibody, no reaction occurs between cells and 
secondary antibodies (Figure 4.3). Cell surface antigen expression was observed to be 
positive for CD44 (Figure 4.4) and CD117 (Figure 4.5) which are known as rat MSC 
markers. In addition, cells were negative for hematopoietic ce ll surface marker CD34, 
which validating that cells were MSCs (Figure 4.6). 
. 
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Figure 4.3: Immunostaining identification of BM-MSCs on the basis of surface marker 
expression (Negative Control): A) The nuclei stained with DAPI (blue), B) Secondary 
antibodies employed were Alexa fluor 546 (red) conjugated IgGs, which was negative, and 
C) Merged image indicated the negative reaction of the marker protein in the absence of 
primary antibody ( magnifications: X200).  
 
A 
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Figure 4.4: Immunostaining identification of a BM-MSC on the basis of CD44 positive 
expression, (magnifications: X400). A) The single nuclei stained with DAPI (blue), B) 
Secondary antibodies employed were Alexa fluor 546 (red) conjugated IgGs and C) 
Merged image indicated the positive reactivity of marker proteins. This image showed 
cells were positive for CD44, which validated that the cells were MSCs. 
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  Figure 4.5: Immunostaining identification of MSCs on the basis of CD117  positive 
expression, (magnification: X400). A) The nuclei of MSCs stained by DAPI (blue), B) 
Secondary antibodies employed were Alexa fluor 546 (red) conjugated IgGs and C) 
Merged indicated the positive reactivity of marker proteins. Cells were positive for CD117, 
which confirmed the fibroblast- liked cells were MSCs rather than hematopoietic stem 
cells. 
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 Figure 4.6: Immunostaining identification of BM-MSCs on the basis of CD34 negative  
expression, (magnification: X400). A) DAPI stained the nuclei blue, B) Secondary 
antibodies did not bind to primary antibodies, and C) merged image indicated the negative  
reactivity of marker proteins. Secondary antibodies employed were Alexa fluor 546 (red) 
conjugated IgGs. Hence, undifferentiated BM-MSCs were negative for CD34, a known 
cell surface marker for hematopoietic cells. This result also validated that the fibroblast-
liked cells were MSCs rather than hematopoietic stem cells. 
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4.1.4 FACS Analysis of BM-MSCs 
Fluorescence-activated cell sorting (FACS) analysis was further performed for the cell 
population count of MSCs against CD44 (known MSCs marker) and CD45 (hematopoietic 
marker). To note, unlabeled cells (blank control) and cells with only secondary antibody 
(negative control) were used as a reference in this study where both of them should give 
about the same results. Cells were trypsinized, labeled with antibodies against the indicated 
antigens and analyzed by FACS in triplicates. Green Alexa Flour 488 goat anti-mouse was 
used as secondary antibody.  
The FACS analysis revealed that untreated MSCs were more than 85% positive for CD44 
(Figure 4.7 (B)). While MSCs showed to be more than 60%, 85% and 82% negative for 
CD45, unlabeled cells (blank control) and negative control (only secondary antibody) 
respectively. These results, along with morphological characteristics, indicated that the 
cultured BM-MSCs populations were almost mesenchymal stem cells and most of the 
HSCs had been removed.  
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 Figure 4.7: FACS analysis of cell surface markers (CD44) and (CD45) of BM- MSCs. 
The filled histograms refer to specific surface markers. (A) Blank control or unlabeled cells 
with no antibodies: cells showed about 85%  negative, (B) cells were positive (85%) for 
CD44  which confirmed that more than 85% of cells were mesenchymal stem cells. (C) 
MSC cells were 60% negative for CD45 with partially 30% positive, (D) cells were treated 
only with secondary antibodies (IgG Alexa Flour 488) were 82% negative which 
confirmed the purity of the antibody stock that had been used.  
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4.2 Differentiation of BM-MSCs into Cardiomyocytes-like Cells 
4.2.1 Characteristics of Differentiated MSCs after Treatment  
 The induction of cardiomyocyte- like cells from MSCs was successfully performed. 
In this study, to induce myocardial differentiation, MSCs at 70-80% confluence were 
incubated in serum-containing medium (DMEM) supplemented with 3µM 5-azacytidine 
and zebularine separately for 24 hours, and subsequent culturing in complete medium 
(DMEM) up to 20 days. After exposure to 5-azacytidine and zebularine, changes in 
morphology were observed. During exposure, some adherent cells died, and the surviving 
cells began to proliferate and differentiate. The morphology of the MSCs changed, with the 
remaining adherent cells enlarging and forming a ball- liked appearance, or lengthening in 
one direction forming a stick-like morphology (Figure 4.8).  Towards the end, the cells 
changed into myocyte- like cells along with cluster- like aggregates.  
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Figure 4.8: Phase contrast imaging of the morphological modification of the BM-MSCs 
before and after treatment with 5-azacytidine and zebularine. (A-B): Primary BM-MSCs 
showing spindle- like morphology after being seeded in complete DMEM. A: 48 hours; B: 
10 days after seeded (scale bars: 100 µM). (C-D): Morphology of BM-MSCs after 
treatment with 5-azacytidine and zebularine respectively. After exposure, the morphology 
of the MSCs changed, some adherent cells died, and the surviving cells began to 
proliferate, differentiate and started to enlarge showing ball- like or stick- like cells 
morphology after 20 days of treatment (scale bars: 100 µM). 
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4.2.2 Expression of Cardiac Specific mRNA in Treated and Untreated MSCs 
 The mRNA expression of cardiomyogenic specific markers of untreated and treated 
MSCs with 3µM of 5-azacytidne and zebularine were assessed by reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis (Figure 4.9). The housekeeping gene 
GAPDH was employed for internal normalization of RNA. The amplicon of GAPDH was 
found in both undifferentiated and differentiated MSCs indicating that GAPDH remained 
activated in both treated and untreated cells. RT-PCR analysis revealed the presence of 
cardiac alpha myosin heavy chain (CAMHC), cardiac troponin-T (cTnT) and cardiac 
transcription factors (GATA-4) amplicon in treated MSCs. However, very low intensity 
bands of selected cardiac specific genes were observed in untreated MSCs. In addition 
cardiac transcription factors (GATA-4) band was not observed in untreated MSCs.  
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Figure 4.9: Expression of cardiac specific genes in treated BM-MSCs: The amplicon of 
GAPDH was strongly detected in both untreated and treated MSCs. Reverse Transcriptase 
(RT) PCR analysis showed the amplicon presence of CAMHC, cTnT and GATA-4 in 
treated MSCs.  
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4.2.3 Densitometry Analysis 
Densitometry analysis was performed to measure the integrated density value (IDV) of 
each band. Relative quantification of each band was performed using gel documentation 
system and IDV of each band was compared with the corresponding GAPDH band. The 
gene expression level of CAMHC (Figure 4.10 (A)), cTnT (Figure 4.10 (B)) and GATA-4 
(Figure 4.10 (C)) were significantly increased after treatment compared to untreated cells. 
CAMHC had the highest expression, whereas GATA-4 showed the lowest expression 
compared to CAMHC and cTnT after treatment with 5-azacytidine and zebularine. While 
selected cardiac specific gene expression level were slightly higher in 5-azacytidine treated 
cells compared to zebularine, however there were no significant differences between 5-
azacytidine and zebularine treated cells. This indicated that besides 5-azacytidine, 
zebularine could be a good candidate for MSCs induction into cardiomyocytes. Data 
obtained were presented as average (mean ± SD; standard deviation) and calculated using 
Microsoft Excel. Statistical significance (*p<0.05) was determined using SPSS software 
and subjected to t-test to determine a significant difference of the gene expression level 
between differentiated and undifferentiated cells.  
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Figure 4.10: Relative gene expression level of cardiac specific genes in treated MSC:  (A) 
CAMHC, (B) cTnT and (C) GATA4 expression level against GAPDH which was used to 
normalize the cellular mRNA level in untreated and treated MSCs.  CAMHC, cTnT and 
GATA-4 expression were significantly higher in treated MSCs with 5-azacytidine and 
zebularine compared to untreated MSCs.   
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CHAPTER 5 
DISCUSSION 
5.1 General Discussion 
 Cardiovascular diseases particularly myocardial infarction (MI) is the leading cause 
of death in the world. This is because most of the cardiomyocytes become differentiated 
immediately after birth; hence causing limited or no capacity of adult cardiac musc le  to  
regenerate damaged area following MI (Burlacu et al., 2008). The use of bone marrow 
mesenchymal stem cells (BM-MSCs) and progenitor cells is actively tested as cell-based 
therapeutics to restore function of post-MI. Therefore, these cell-based therapies are paving 
a path to novel treatment approaches (Webster, 2005; Tendera et al., 2009).  BM-MSCs are 
adult multi-potential progenitor cells, which have the potential to differentiate into various 
tissues under appropriate culture condition. BM-MSCs are being aggressively explored for 
their potential and action in affecting the repair of cardiac tissue after myocardial infarction 
and have shown the ability to trans-differentiate into cardiomyocytes, both in vitro and in 
vivo (Li et al., 2007; Jackson et al., 2007). Cell-based treatment using BM-MSCs have 
resulted in encouraging and promising results for the treatment of MI (Shi et al., 2011; 
Kim et al., 2011; Li et al., 2012; Raynaud et al., 2013).  
 In this study, rat BM-MSCs were successfully isolated by a property of adherence 
to plastic. After 2-3 days isolation of MSCs and frequent changing of culture medium, 
BM-MSCs adhered to the surface of flask in small quantity and scattered about showing 
spindle-shaped or fibroblast-like morphology (Figure 4.1), parallel to previous studies. 
Naeem et al. (2013), Jianquan et al. (2012), Antonitsis et al. (2007) and Li et al. (2002) 
reported the phase contrast microscopy of MSCs revealed as small, bright with fibroblast-
like morphology in primary culture.  
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 While there is a wide range of surface markers that have been tested to characterize 
MSCs, there is currently no single set of phenotypic markers used to identify a MSC. 
Therefore, isolated MSC populations are still not entirely homogenous (Peister et al., 2004; 
Rastegar et al., 2010; Williams & Hare, 2011). In this study, after morphological 
identification of BM-MSCs, they were further characterized for the positive presence of 
selected known MSCs markers: CD44, CD117, and absence of hematopoietic markers 
CD34, CD45 using flow cytometry and immunocytochemistry.  
  Cytometric analysis showed that the isolated MSCs strongly expressed the known 
surface markers of MSCs, such as CD44 (85%) (Figure 4.7(B)). The FACS analysis also 
revealed that unlabeled cells (no antibody) and cells with only secondary antibody 
(negative control) were observed to be 85% (Figure4.7 (A)) and 82% (Figure 4.7 (D)) 
negative respectively. Unlabeled cells (blank control) and cells with only secondary 
antibody (negative control) were used as reference in this study where both of them should 
give about the same result as both of them used as negative control. MSCs were also more 
than 60% negative for the hematopoietic surface marker CD45 with partially positive 
(30%) which could be due to contaminations of other cells for example endothelial cells 
(Figure 4.7 (C)). 
 Furthermore, immunocytochemistry results showed cultured cells were positive for 
the well defined MSCs markers, such as CD44 (Figure 4.4), CD117 (figure 4.5) and 
negative for CD34 (Figure 4.6), one of the well known hematopoietic surface markers. 
Cells were also treated only with secondary antibodies (Alexa Flour 546) as a negative 
control (Figure 4.3). This negative control showed that in the absence of primary antibody, 
no reaction occurred between cells and secondary antibodies which validated and 
confirmed completeness of the experimental procedures. The surface marker expression 
profile accords well with previous studies (Bruder et al., 1998; Colter et al., 2000; Javazon 
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et al., 2001; Naeem et al., 2013). The absence of CD34 and CD45, have been widely 
accepted as the major differences between MSCs and hematopoietic stem cells (HSCs) 
(Colter et al., 2000). Based on the expression of a panel of surface markers, the results of 
this study support the identity of isolated cells as MSCs. Variable expression of cell 
surface markers has also been observed due to variation in tissue source, isolation and 
culture methods (Vacanti et al., 2005; Faast et al., 2006; Ock et al., 2010; Kumar et al., 
2012).  
 Trans-differentiation potential of MSC into cardiac cell types has been explored 
extensively, with several groups reporting that these stem cells can trans-differentiate into 
cardiomyocytes (Tomita et al., 1999; Orlic et al., 2001; Rastegar et al., 2010; Williams et 
al., 2011; Naeem et al., 2013). However, the environmental-driven differentiation of 
uncommitted stem cells is difficult to anticipate and may result in other cell types (Balsam 
et al., 2004). One alternative strategy for overcoming ineffective differentiation is the 
pretreatment of stem cells to turn them into progenitor cells before becoming adult cells 
(Rosca & Burlacu, 2011). There have been some small molecules such as dexamethasone, 
ascorbic acid, 5-azacytidine, or all-trans retinoic acid which are capable of inducing the 
differentiation of stem cells into different cells types (Ding & Schultz, 2004; Rosca & 
Burlacu, 2011; Naeem et al., 2012). 
 In the present study, after successful isolation and characterization of bone marrow 
derived MSCs, the effect of two DNA demethylating agents on differentiation potential of 
BM-MSCs into cardiomyocytes were investigated. BM-MSCs were treated separately with 
3µM optimized concentrations of 5-azacytidine and zebularine, as described by Naeem and 
coworkers (2013). 5-azacytidine is the most popular chemical for inducing stem cells into 
cardiomyocytes. 5-azacytidine is analogue of cytidine and it can form covalent conjunction 
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compound with DNA. It is hypothesized that the treatment of cells by 5-azacytidine makes 
the cells less responsive to other inductive factors secreted by the microenvironment that 
might modulate the differentiation (Rosca & Burlacu, 2011). Zebularine, a cytidine analog 
containing a 2-pyrimidinone ring, is another novel DNA methyltransferase (DNMT) 
inhibitor, which have been developed as a more stable and less toxic drug compared to 5-
azacytidine (Yoo et al., 2004; Naeem et al., 2013). Zebularine could be a good candidate 
for inducer as an alternative to 5-azacytidine which is less stable and more toxic.  
 The present study demonstrated that demethylating agents, 5-azacytidine and 
zebularine could induce changes in BM-MSCs leading to their differentiation in vitro and 
directing them towards the cardiomyogenic lineage. Morphological results showed that 
fibroblast- liked cells gradually increased in size after exposure to 5-azacytidine and 
zebularine. It was observed that a certain concentration of 5-azacytidine and zebularine 
changed rat MSCs morphology and promoted the cells to form mytube structures after two 
weeks of treatment (Figure 4.8).   
 Notably, data from reverse transcriptase (RT)-PCR revealed the presence of 
cardiac-specific genes, including alpha myosin heavy chain (CAMHC), cardiac troponin-T 
(cTnT) and cardiac transcription factor (GATA4) after treatment with 5-azacytidine and 
zebularine. However, a very low intensity band of selected cardiac markers were observed 
in untreated MSC cells. GAPDH is a housekeeping gene, which has always been activated 
by all mammalian cells by undifferentiated or differentiated cells (Barber et al., 2005). 
GAPDH amplicon was strongly presented in cells, both before and after differentiation, 
indicating that GAPDH remains activated in both types of cells (Figure 4.9).  
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 Densitometry analysis showed that selected cardiogenic genes expression levels 
increased significantly after induction (Figure 4.10). CAMHC which is one of the known 
structural gene in cardiomyogenesis (Planat-Bernard et al., 2004) showed a modest 
increase in expression after treatment. After CAMHC, another known cardiac structural 
gene (cTnT), and cardiac transcription factor (GATA-4) had the highest expression in 
treated MSC cells respectively. GATA-4 and Nkx2.5 were known as key regulator in 
cardiac development (Planat-Bernard et al., 2004) and GATA-4 expressed during 
myocardium development (Charron & Nemer, 1999; Shirinsky et al., 2008). GATA 
transcription factors are involved in the expression of many genes, which encode for 
contractile proteins like cardiac troponinT and cardiac alpha actin (Shirinsky et al., 2008). 
 Moreover, RT-PCR analysis showed that the cardiac markers gene expression level 
of 5-aza treated cells were slightly higher than those of zebularine treated cells. However, 
no significant differences were observed. This supports the procedure that pre-treatment of 
BM-MSCs with 5-azacytidine or zebularine might facilitate the differentiation towards 
cardiomyogenic lineage under in vivo conditions. Previous studies have also proven the 
ability of MSC cells to differentiate and express cardiomyogenic genes after in vitro 
treatment with 5-azacytidine. First Makino et al. (1999) induced the marrow stromal cells 
from adult mouse with 5-azacytidine, and obtained self-contractile myotube structure cells 
agglomerates which the structure looked like embryonic cardiomyocytes. Following this 
report, several studies showed that MSCs could differentiate into cardiomyocytes after 
treatment with 5-azacytidine ( Fukuda, 2003; Xu et al., 2004; Antonitsis et al., 2007; 
Burlacu et al., 2008; Naeem et al., 2013). 
 Although the effects of 5-azacytidine on bone marrow mesenchymal stem cells 
have been widely studied, there is little evidence of zebularine being directly involved in 
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stem cell differentiation (Liu et al., 2003; Antonitsis et al., 2007; Burlacu et al., 2008). The 
results of this study showed that there were no significant differences between gene 
expression levels of 5-azacytidine and zebularine treated cells, although both increased 
expression of selected cardiac markers significantly after treatment. However, further 
studies need to be done to assess the mechanism and differentiation potential of zebularine 
into cardiomyocytes both in vitro and in vivo. The potential of zebularine was widely 
studied in microbial systems, cancer therapy, as well as mammalian cell lines (Cheng et 
al., 2003). Cheng and colleagues (2003) reported that zebularine and 5-azacytidine can 
induce the expression of the myogenic phenotype in mouse embryonic fibroblast cells and 
inhibited the methylation of specific loci in both the mouse CII-d and human p16 
promoter. This study agrees with proposed of Naeem and his colleagues (2013) on 
zebularine that it could be used as a new candidate for cardiomyogeneic inducer. With 
better stability and less cytotoxic potential, zebularine could be a good replacement for 5-
azacytidine for differentiation of MSCs into cardiomyocytes. 
 It is worth noting that even though the cardiac specific genes were up regulated and 
expression increased after 5-azacytidine and zebularine treatment, they were also found to 
be present in untreated cells, in accordance with previous data that suggested a promoting 
rather than inductive effect of myogenic gene transcription (Burlacu et al., 2008; Rosca & 
Burlacu, 2011). This is also in accordance with the hypothesis that the transcriptional 
machinery of adult stem cells is operating at a low level, but is not silenced, such that these 
cells express a variety of gene families that characterize differentiated progeny (Zipori, 
2004; Rosca & Burlacu, 2011). Rosca and Burlacu (2011) stated that treatment of MSC 
with 5-azacytidine may promote subsequent cardiac differentiation but it is dependent on 
finding the adequate conditions for cardiomyogenic differentiation. Correct concentration 
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of 5-azacytidine coupled with the use of growth factors and cytokines may be able to 
create an adequate conditions for cardiomyogenic differentiation. Rangappa et al. (2003) 
also stated that 5- azacytidine promotes rather than induces the myogenic differentiation of 
bone marrow progenitor cells as it enhanced the appearance of myogenic markers.  
According to this hypothesis, adult stem cells are in a standby state, prepared to 
differentiate at any moment. Taken all together, these results suggested that, 5-azacytidine 
and zebularine promoted changes in phenotype by expressing markers and activating  
cardiac specific genes. It can be expected that treated MSCs prior to transplantation may 
increase the likelihood of successful regeneration of damaged myocardium in vivo 
environment. Because the cells would be still multipotent at the time of transplantation and 
also more open to the subsequent differentiation stimuli. 
5.2 Limitations and Future Studies  
 Despite of BM-MSCs differentiation and expression of cardiac specific genes by 5-
azacytidine and zebularine, treatment by these components alone may not be sufficient to 
sustain terminal differentiation of MSCs into cardiomyocytes. Pre-treatment of BM-MSCs 
with 5-azacytidine and zebularine before transplantation could facilitate the differentiation 
towards cardiomyogenic lineage under in vivo conditions.  Following this priming step, the 
cardiac differentiation process could be completed in vivo by the factors within the cardiac 
environment. It would be worthwhile to investigate whether the treatment of multipotent 
stem cells with demethylating agents such as 5-azacytidine and zebularine prior to 
transplantation can direct them towards specific cardiomyogenic lineage in the in vivo 
environment.  
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CHAPETR 6 
CONCLUSION 
 
          In this study, successfully isolated and cultured cells displayed the typical fibroblast-
like morphology and surface antigen profile of bone marrow mesenchymal stem cells 
(BM-MSCs). Further, distinctive morphological characteristics and the expression of genes 
specific to cardiac myocytes supported their potential to differentiate in vitro into 
cardiomyocyte- like cells upon exposure to 5-azacytidine and zebularine.  
        In vitro cardiomyogenic differentiations of rat BM-MSCs, thus, offer a suitable model 
to understand their molecular and functional identities prior to transplantation.  These 
results suggested that, 5-azacytidine and zebularine induce changes in phenotype by 
expressing markers and activating specific genes, but its treatment alone may not be 
sufficient to sustain terminal differentiation of MSCs into cardiomyocytes. Besides 5-
azacytidine, which is a well known compound, zebularine as a new candidate could be a 
good replacement for differentiation of mesenchymal stem cells into cardiomyocytes 
because of its stability and less toxicity to biological systems. In order to assure the quality 
of the final therapeutic product, it is however important to evaluate the differentiation 
potential’s stability in vivo. This would enhance the rate of bone marrow stem cell 
differentiation into mature cardiomyocytes in the injured heart. 
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Appendix A: List of Apparatus, Chemical and Material 
1. Apparatus 
Dissecting set, Disposable syringe, Syringe filters, 26-gauge needles, Electronic shaker, 
Magnetic stirrer, Microwave oven, Ice cubes, 75 and 25 cm3 tissue culture flasks with 
vented cap (Iwaki, Japan), Blue cap tube (Bioscience, Germany), Thermo scientific Nunc 
Lab-Tek II Chamber Slide System, Falcon tubes (Eppendorf, Germany), Spin columns 
(Promega, USA), Collection tubes (Promega, USA), Pipettor (Eppendorf, Germany), 
Elution tube (Promega, USA), Quartz cuvettes (Shimadzu, Japan), Microcentrifuge tube ( 
Eppendorf, Germany), Class II, type A2 Biohazard safety cabinet (ESCO, Singapor), 5% 
CO2 incubator ( NuAir, USA), Phase contrast microscope (Nikon, Japan), Fluorescence 
inverted microscope (Nikon, Japan), Flow cytometer (Becton Dickinson, USA), 
Spectrophotometer (Shimadzu, Japan), Thermal cycler (Eppendorf, Germany).  
2. Chemical and Materials: 
 
 1X phosphate buffer saline (PBS) 
 Alcohol 70% 
 Dulbeco’s Modified Eagle Medium (DMEM) (Gibco, USA) 
 10% (2.5%) Trypsin-EDTA 
 4% paraformaldehyde (PFA) 
 Triton-X100 
 4’, 6-Diamidino-2-phenylindone (DAPI), blue dye 
 Distilled water  
 Cell dissociation buffer, enzyme free, Hank’s based (Gibco, USA)  
 1% Bovine Serum Albomin (BSA) 
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 0.1% sodium azide  
 14.3 M b-Mercaptoethanol 
 95% EtOH 
 Deionized water  
 0.1% Diethylpyrocarbonate (DPEC) treated water  
 10 Mm Tris-EDTA buffer 
 M DTT 
 25 Mm MgCl2 
 1% Agarose powder 
 10mg/ml ethidium bromide  
 Tris base  
 Boric acid  
 DNA ladder 
 
3. Antibodies  
 
 Primary antibody CD34 (Bioscience, USA) 
 Primary antibody CD44 (Bioscience, USA) 
 Primary antibody CD45 (Bioscience, USA) 
 Primary antibody CD117 (Bioscience, USA) 
 Secondary antibody green Alexa Flour, 488 goat-anti-mouse IgG (H+L) 2mg/ml 
 Secondary antibody red Alexa Flour, 546 goat-anti-mouse IgG (H+L) 2mg/ml 
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4. Primers  
 
 Glyceraldehyde-3phosphate dehydrogenase (GAPDH) (IDT, USA) 
 Myocardium Cardiac alpha heavy chain (CAMHC) (IDT, USA) 
 Cardiac troponin-T (cTnT) (IDT, USA) 
 Cardiac transcription factors (GATA-4) (IDT, USA) 
 
5. Kits: 
 
 SV Total RNA isolation system (Promega, USA) 
 RevertAidTM  first cDNA synthesis kit (Thermo Scientific, USA) 
 Fermentas Life Science’s PCR kit (Thermo Scientific, USA)  
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Appendix B: Stock Preparation 
 
1. Stock solution preparation of 5-azacytidine : 
 
In order to make 10mM stock solution: 
Molecular weight of 5-azacytidine: 244.24 g/mol 
      10 mM= 0.01 Mole 
MW of 5aza = 244.24g/mol 
0.01M x 244.24 g/mol = 2.4424 mg 
2.4424 mg of 5-aza dissolve in 1 ml of sterile water              2.4424 mg/ml 
 
In order to make 3uM concentration of 5-aza: 
M1 V1= M2 V2 
(10) mM x (V1) =(3)uM  (13) ml                V1 = 3.9 uL of 5-azacytidine 
 
2. Stock solution preparation of Zebularine: 
 
In order to make 10mM of stock solution: 
Molecular weight of zebularine: 228.20 g/mol 
10 mM= 0.01 Mole 
0.01m x 228.20 g/mol= 2.2820 mg 
2.2820 mg of zebularine dissolve in 1 ml of sterile water             2.2820 mg/ml 
 
In order to make 3uM concentration of zebularine: 
M1 V1= M2 V2 
(10) mM x (V1) =(3) uM  (13)ml                  V1  = 3.9 uL of zebularine 
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3.  5X TBE buffer preparation for gel electrophoresis  
Components                                                                                     Amount  
Tris base                                                                                              54 gm 
Boric acid                                                                                            27.5 gm 
EDTA                                                                                                  1.861 gm 
dH2O                                                                                                    up to 1 L 
 
 
4.  Agarose gel preparation 
Components                                                                                              amount  
5X TBE buffer                                                                                          10 ml 
Distilled water                                                                                           40 ml 
1% agarose powder                                                                                   0.5 gm 
Ethidium bromide                                                                                      1.5 uL 
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Appendix C: Publications 
1. Publication:  
Noorezatey M, Khairul Fidaa K.B., Ramin K. Maizatul Fazilah AR, Anbarieh S, Shamsul    
        Azlin AS, and Durriyyah Sharifah HA. Visual confirmation of isolated bone marrow   
        mesenchymal stem cells and differentiated cardiomyocyte-like cells. Malaysian  
        Journal of Microscopy. Vol 9, November 2013. ISSN 1823-7010. pg 145-148.  
         
 
2. Publications in conference:  
1. Ramin K, Noorezatey M, Khairul Fidaa KB, Maizatul Fazilah AR, Anbarieh S,    
            Shamsul Azlin AS, Durriyyah Sharifah HA and Asmat S. Differentiation potential     
            of rat bone marrow mesenchymal (BMMSCs) into cardiomyocyte- like cells affer  
            zebularine and 5-azacytidine treatments. 38th Annual Conference of the Malaysian  
            Society for Biochemistry and Molecular Biology (MSBMB). Putrajaya Marriott   
            Hotel & Spa, Putrajaya, Malaysia. 28-29 August 2013. 
 
2.Noorezatey M, Khairul Fidaa K.B., Ramin K. Maizatul Fazilah AR, Anbarieh S,    
Shamsul Azlin AS, Durriyyah Sharifah HA. and Asmat, S. Visual confirmation of 
isolated bone marrow mesenchymal stem cells and differentiated cardiomyocyte-
like cells. 22nd Scientific Conference of Microscopy Society Malaysia (MSM 2013). 
Primula Beach Hotel, Kuala Terengganu, Terengganu, Malaysia. 26-28 November 
2013. 
 
3.Anbarieh S, Maizatul Fazilah AR, Ramin K, Shamsul Azlin AS, Durriyyah SharifahHA  
           Asmat S. Preliminary study: Differentiation of bone marrow mesenchymal stem  
           cells into neuronal- like cells by β-mercatoethanol and confirmation through  
           morphopogical features. 4th International NeuroMalaysia Society Symposium.         
           MonashUniversity Sunway Campus, Malaysia. 28 September 2013. 
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